Histological and Top-Down Proteomic Analyses of the Visual Pathway Using the Cuprizone Demyelination Model

Mohammed S. M. Almuslehi

University of Diyala

Monokesh K. Sen (✉ monokesh.sen@sydney.edu.au)

The University of Sydney <https://orcid.org/0000-0003-3988-9196>

Peter J. Shortland

Western Sydney University

David A. Mahns

Western Sydney University

Jens R. Coorssen

Brock University

Research Article

Keywords: optic nerve, optic tract, optic neuritis, proteoforms, bioinformatics 2D gel electrophoresis, mass spectrometry

Posted Date: December 8th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-1129433/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

A change in visual perception is a frequent early symptom of multiple sclerosis (MS), the pathoetiology of which remains unclear. Following a slow demyelination process caused by 12 weeks of low-dose (0.1%) cuprizone (CPZ) consumption, histology and proteomics were used to investigate components of the visual pathway in young adult mice. Histological investigation did not identify demyelination or gliosis in the optic tracts, pretectal nuclei, superior colliculi, lateral geniculate nuclei or visual cortices. However, top-down proteomic assessment of the optic nerve/tract revealed a significant change in the abundance of 34 spots in high-resolution 2D gels. Subsequent liquid chromatography-tandem mass spectrometry analysis identified alterations in 75 proteoforms. Literature mining revealed the relevance of these proteoforms in terms of proteins previously implicated in animal models and human MS. Importantly, 24 proteoforms were not previously described in any animal models of MS or MS itself. Bioinformatic analysis indicated involvement of these proteoforms in cytoskeleton organization, metabolic dysregulation, protein aggregation, and axonal support. Collectively, these results indicate that continuous CPZ-feeding, which evokes a slow demyelination, results in proteomic changes that precede any clear histological changes in the visual pathway and that these proteoforms may be potential early markers of degenerative demyelinating conditions.

Introduction

The optic nerve/tract is responsible for the relay of information from the retinal ganglion cells to the primary visual cortex via the lateral geniculate nucleus (Rizzo, 2005; Selhorst and Chen, 2009). Any insult to the optic pathway results in changes in visual perception (Athappilly et al., 2008; Dutton, 2004; Kiyota et al., 2017). A common example of this is optic neuritis, a demyelinating and acute inflammatory disorder (Costello, 2016; Kale, 2016). Optic neuritis has been attributed to several etiologies including genetics, inflammation, infections, and exposure to toxic substances, and it is highly associated with multiple sclerosis (MS; Costello, 2016; Kale, 2016); however, the pathoetiology of optic neuritis and MS-associated changes in vision are not clearly defined. It has been suggested that central nervous system (CNS) demyelination and inflammation are initiated in a slow and progressive manner that may start several years prior to the onset of clinical symptoms (Jones-Odeh and Hammond, 2015; Olesen et al., 2019; Sen et al., 2020a; Stys et al., 2012). Moreover, changes in visual perception (e.g. blurring, eye fatigue, lack of sharpness, ocular pain) can also be seen in other neurodegenerative disorders such as Alzheimer's and Parkinson's diseases (Colligris et al., 2018; Kesler and Korczyn, 2006). Like MS, in which the mechanism of visual disturbances is still unknown, the pathoetiology of visual disturbances in Alzheimer's and Parkinson's has also not been identified.

These demyelination-related changes can be investigated using the cuprizone (CPZ; bis(cyclohexanone)oxaldihydrazone) animal model (Sen et al., 2020a; Sen et al., 2019b). This model was initially used to study de- and re-myelination and the innate immune response (Goldberg et al., 2015; Kipp et al., 2009; Matsushima and Morell, 2001; Praet et al., 2014; Sen et al., 2019b). More recently, the CPZ model has been modified to investigate adaptive immune responses in the CNS (Almuslehi et al., 2020; Capriarello et al., 2018; Sen et al., 2019a). In this model, animals are fed CPZ, which is preferentially toxic to mature oligodendrocytes, inducing oligodendrocytosis (i.e. loss or degeneration of oligodendrocytes) and subsequent demyelination, as well as micro- and astro-glial activation (Almuslehi et al., 2020; Sen et al., 2020b; Sen et al., 2019a). The mechanisms underlying oligodendrocytosis induced by CPZ are still poorly understood. It has been proposed that the metal (e.g. copper) chelating properties of CPZ disrupt metabolic processes in oligodendrocytes due to the inhibition of mitochondrial enzymes (reviewed in Sen et al., 2019b). However, very little is known about the actions of CPZ on the visual pathway, and much of what is reported is contradictory (reviewed in Sen et al., 2019b). One histological investigation found a reduction of myelin basic protein in optic nerves (Namekata et al., 2014) whereas no loss of myelin protein was observed in other studies (Araujo et al., 2017; Goldberg et al., 2015; Sen et al., 2020b; Yang et al., 2009). However, different experimental paradigms were used in these studies (e.g. dose, duration of CPZ-feeding and (immuno)histological staining techniques). Thus, feeding C57Bl/6 mice with 0.2% CPZ for 12 weeks led to a reduction of myelin basic protein in the optic nerve, which was unchanged in the first 6 weeks of CPZ-feeding (Namekata et al., 2014). Yet, feeding 0.2% CPZ for 3 or 5 weeks did not produce any changes in mRNA expression of myelin basic protein in optic nerve (Araujo et al., 2017). Another investigation showed no changes in myelin proteolipid protein when mice were fed with 0.25% CPZ for 5 weeks (Goldberg et al., 2015). Likewise, we showed that feeding 0.2% CPZ for 5 weeks did not result in loss of myelin in the optic nerve/tract when silver staining was used for myelin detection (Sen et al., 2020b). These findings indicate that changes in optic nerve/tract myelin status may rely on the dose of CPZ, duration of exposure, or method used to assess myelin status. However, using an autoimmune animal model of (later stage) MS, ultrastructural analysis of optic nerves in mice subjected to experimental autoimmune encephalomyelitis (EAE) showed axonal demyelination relative to healthy control mice (Manogaran et al., 2019).

Apart from histological alterations, several studies have investigated proteome changes in the CNS of CPZ-fed mice (Martin et al., 2018; Partridge et al., 2016; Sen et al., 2019a; Szilagyi et al., 2020; Werner et al., 2010). However, proteome investigations of the optic nerve/tract of CPZ-fed mice have not been reported in the literature. Likewise, no proteomic investigation of optic nerve/tract was found for any other animal models (e.g. EAE (Krishnamoorthy and Wekerle, 2009)). Proteomic investigation of the visual pathway has been proposed as an approach to better understand the pathoetiology of eye diseases and identify early biomarkers (Semba et al., 2013). Accordingly, this study used coupled histological and proteomic analyses to assess alterations in the visual pathway following 12-weeks of 0.1% CPZ-feeding; this treatment paradigm was chosen because it induces comparable demyelination and gliosis in the corpus callosum but less suppression of the peripheral immune system than 0.2% CPZ (Almuslehi et al., 2020; Sen et al., 2019a). Due to this slow demyelination process, we hypothesized that CPZ-induced changes in the proteome of the visual pathway would be consistent with those underlying changes in visual perception in MS and other neurodegenerative eye diseases.

Here the histological investigation focussed on the visual pathway (Huberman and Niell, 2011; Seabrook et al., 2017) from the optic nerve/tract to the visual cortex, including its subcortical relay nuclei (pretectal, superior colliculi and thalamic lateral geniculate nuclei). The proteomic investigation was carried out using optic nerve/tract tissue that extended from the posterior part of eyeballs to the end of the visible part of the optic tract (posterior to the optic chiasm and before the lateral geniculate body) in order to ensure there was no contamination with other CNS tissue/proteins. The other visual components (e.g. pretectal nuclei, superior colliculi, lateral geniculate nuclei and visual cortex) were thus excluded from the proteomic analysis. We used a well-established, high resolution top-down proteomic analysis - two-dimensional gel electrophoresis coupled with liquid chromatography and tandem mass spectrometry (2DE/LC-

TMS) - rather than the inferred sequencing of canonical proteins (i.e. shotgun proteomics) in order to resolve and identify proteoforms (i.e. protein species) - the active biological entities (Aebersold et al., 2018; Coorssen and Yergey, 2015; Oliveira et al., 2014; Sen et al., 2021; Zhan et al., 2019). Following identification, proteome changes in the optic nerve/tract of the CPZ model were compared to published proteome data on MS patients and MS animal models from analyses of a variety of samples including cerebrospinal fluid, CNS tissue, and tears to search for possible correlations.

Materials And Methods

Animals and feeding

Adult (seven-week-old) male C57Bl/6 mice (n=20) were purchased from the Animal Resources Centre, Australia (www.arc.wa.gov.au). Mice were acclimatized for one week and housed (2 animals/ventilated GM500 cage, Tecniplast, Italy) in a controlled environment (12-hours light/dark cycle, 50-60% humidity and 21-23°C) in the animal facility (School of Medicine, Western Sydney University). Standard rodent powder chow (Gordon's Specialty Stockfeed, Australia) and water were available *ad libitum*.

Age/weight-matched mice were randomly divided into control (Ctrl) or CPZ groups (n=10 mice/group). CPZ (Sigma-Aldrich, St. Louis, MO, USA; 0.1% w/w) was mixed with powdered chow and fed to mice for 12 weeks to induce a slow progressive oligodendrocytosis and demyelination (i.e. more reminiscent of MS (Sen et al., 2020a)). The powdered chow was prepared daily without (for Ctrl group) and with CPZ and provided in excess (*ad libitum*) in a single shared feeder per cage. At the end of 12 weeks, all mice were euthanized for histological and proteomic analyses.

Histology and immunohistochemistry

Quantitative histological examination was performed as previously described (Almuslehi et al., 2020; Sen et al., 2020b; Sen et al., 2019a). Briefly, mice (n=5/group) were deeply anaesthetized with isoflurane (2-3%) and perfused transcardially with cold 0.9% saline followed by 4% paraformaldehyde (PFA, in 0.1M phosphate buffer). Brains (with attached optic tracts) were extracted from the skulls, sectioned coronally (40 µm) and transferred either to 6-well plates containing 0.01M phosphate buffer saline (free-floating for immunohistochemistry) or mounted onto 0.4% gelatine-coated slides (for silver staining). Silver-stained sections (Pistorio et al., 2006) were imaged with bright field microscopy (Olympus Carl Zeiss, Jena, TH, Germany). ImageJ software (<https://imagej.nih.gov/ij/>) was used to analyse the images and the results were plotted as the reciprocal of the light intensity to measure the amount of myelin (Sen et al., 2020b; Sen et al., 2019a). For immunofluorescence staining, ionized calcium-binding adaptor molecule 1 (rabbit anti-IBA 1, 1:1000; Wako, Chuo-Ku, OSA, Japan) and glial fibrillary acidic protein (mouse anti-GFAP Alexa 488, 1:1000; Merck-Millipore, Burlington, MA, USA) were used for the detection of microglia and astrocytes, respectively. GFAP and IBA 1 stained sections were imaged using a fluorescence microscope (Olympus Carl Zeiss, Germany). Quantification of the fluorescence intensity of the stained sections was carried out using ImageJ software (Sen et al., 2020b; Sen et al., 2019a). The anatomical locations of visual pathway components were selected using the Mouse Brain Atlas and previous analyses of the mouse CNS (Paxinos and Franklin, 2012; Sen et al., 2020b).

Top-down proteomics: two-dimensional gel electrophoresis and liquid chromatography-tandem mass spectrometry

2DE was performed using the optimized method described in detail in earlier studies (Butt and Coorssen, 2005; Butt and Coorssen, 2013; Gauci et al., 2013; Noaman et al., 2017; Sen et al., 2019a; Wright et al., 2014) and summarized in Figure 1. Briefly, optic nerves/tracts (from posterior part of the eyeballs to the contact area of the optic tract with the brain tissue, i.e. before the lateral geniculate body) were harvested and rinsed immediately with ice cold 0.01M phosphate buffer saline containing a protease/kinase/phosphatase inhibitor cocktail. The nerves/tracts of each group were pooled due to the very small amount of material, and homogenized in the deep-frozen state, solubilized in HEPES hypotonic lysis buffer (isotonicity of the solution restored by adding 2x phosphate buffer saline, PBS), and ultracentrifuged at 125,000g, 4°C for 3 hours to separate total soluble proteins (SP) from membrane proteins (MP). Then, the pellet was resuspended into 1x PBS and ultracentrifuged (125,000g, overnight at 4°C) to solubilize and separate the remaining SP proteins (Butt and Coorssen, 2005). The EZQ Protein Quantitation Kit (Life Technologies, Eugene, OR, USA) was used according to the manufacturer's instructions to measure the total protein concentration in each fraction (SP and MP), with bovine serum albumin (Amresco, Solon, OH, USA) as the standard. Proteoforms were then resolved in the first dimension based on net charge (isoelectric point, *pI*) and by size (i.e. approximate molecular weight) in the second dimension. Total protein extract (100µg) was passively loaded onto immobilized pH gradient (IPG) strips (7cm, non-linear, pH 3-10; Bio-Rad, Hercules, CA, USA) at room temperature (RT) for 16 hours. The strips were then subjected to isoelectric focusing (IEF, first dimension) using the Protean IEF apparatus (Bio-Rad, USA; 17°C, 10000V, 37500VH) with multiple replacements of the electrode wicks during voltage ramping to facilitate effective desalting. Then, following incubation of the resolved IPG strips with reducing and alkylating reagents as well as SDS, the strips were loaded horizontally on top of hand-cast (8.4cm x 7cm x 0.1cm) SDS-PAGE gels and electrophoresis was carried out at 4°C with an initial voltage of 150V for 5 minutes followed by 90V for 3 hours using the Mini Protean Cell (Bio-Rad, USA). Resolved proteoforms were then detected by incubation in colloidal Coomassie Brilliant Blue (cCBB, G-250, Amresco, USA) for 20 hours followed by de-staining with 0.5M NaCl (5 times x 15 minutes). Gels were imaged individually on the Typhoon™ FLA-9000 gel imager (GE Healthcare, USA) using the same setting for all gels (100µm resolution, 685/>750nm excitation/emission and 600V photomultiplier tube). For each group (Ctrl or CPZ), replicate 2DE gels (n=3) for each SP and MP fraction (i.e. 6 gels per group in total) were resolved to ensure reproducibility and thus reliability of the results.

Quantitative analysis of gel images was carried out by using Delta2D (version 4.0.8, DECODON GmbH, Germany) as described previously (Sen et al., 2019a). Briefly, gel images were grouped for each fraction in each experimental group (e.g. SP gels for Ctrl group). In each comparison (e.g. SP of Ctrl group vs SP of CPZ group), gel images were warped and fused using 'union fusion' to create a master gel image. Spots of the master image were then transferred to each image in their group to ensure that the spots consistently matched (100% matching) in all technical replicates (n=3) in each group. Gel edges and the molecular weight marker lanes were excluded manually. Background-subtracted spot volumes were then tabulated as grey values, including fold changes, relative standard deviation (RSD), and p-values (t-test). Following the assessment of changes in fluorescent spot volumes in the CPZ group gels compared to

Ctrl, candidate spots were selected for further analysis (i.e. proteolytic digestion and LC-TMS). This selection was based on specific criteria: p-value ($p < 0.05$), ratio of grey value > 1.5 -fold (Ctrl vs CPZ), and relative standard deviation (RSD) $< 30\%$. Alterations in the ratio (fold change between CPZ and Ctrl gels) for each selected spot were determined by dividing the average ($n=3$) grey value of a given spot in the CPZ optic nerve/tract gels by the average grey value of the corresponding spot in the Ctrl gels. MW and pI of all selected spots were determined using standards, as previously described (Sen et al., 2019a).

The selected spots were excised manually and digested using 12.5 ng/ μ l trypsin (Promega Corporation, USA) at 4°C for 8 hours. The resulting peptides were analysed using LC-TMS on a Xevo QToF mass spectrometer (Waters, USA) as described (Asgarov et al., 2021; Sen et al., 2019a; Wright et al., 2014). PLG software (Version 2.5, Waters Corporation, USA) and the Swiss-Prot (*Mus musculus*, mouse) database (www.wehi.edu.au) were used for data acquisition and processing, respectively, with the following settings: minimum fragments per peptide: 3; minimum peptides per protein: 2; minimum fragments per protein: 7; maximum false positive rate: 4; maximum protein mass: 250000; fixed modifications: carbamidomethyl (C); variable modifications: oxidation (M); missed cleavages: 1; peptide tolerance: automatic; and fragment tolerance: automatic. Finally, identified proteoforms in each spot had to satisfy specific criteria (i.e. protein score ≥ 100 , sequence coverage $\geq 5\%$, unique matched peptides ≥ 3 , and the false-positive rate $< 0.01\%$) in order to be included for further assessment.

Bioinformatics and Literature mining

Functional annotations of identified proteoforms were analysed via bioinformatic analyses (Asgarov et al., 2021; Sen et al., 2021; Sen et al., 2019a). Briefly, the UniProt accession number, gene ID, and subcellular localization of the canonical protein corresponding to each identified proteoform were obtained from the publicly accessible UniProt database (www.uniprot.org). Protein analysis through evolutionary relationships (PANTHER, www.pantherdb.org) was used to define canonical protein classes and biological processes (Mi et al., 2018). In addition, identified protein species were further characterized and grouped to investigate their potential interaction with other proteins (protein-protein interactions, PPI) using the search tool for the retrieval of interacting genes/proteins (STRING, string-db.org) database (Szklarczyk et al., 2018). A PPI map was then generated using STRING in which each node represents one canonical protein (indicated by gene ID) and the connecting lines represent confidence/strength of association (i.e. increasing line thickness reflects the potential for interaction). Finally, a comprehensive PubMed literature search (www.ncbi.nlm.nih.gov/pubmed/) was applied to identify the molecular functions of the proteoforms and their relevance to previous associations with animal models of MS (e.g. CPZ, EAE) and MS itself (Table 1). Moreover, previously identified changes in the abundance of canonical proteins in different CPZ (4), EAE (13), and MS (13) studies using various samples other than optic nerve/tract (e.g. cerebrum, cerebrospinal fluid, tears) were also compared with the current data. Out of six MS-like animal models - EAE, CPZ, ethidium bromide, lysolecithin, diphtheria toxin, and Theiler's virus (Procaccini et al., 2015; Ransohoff, 2012; Traka et al., 2010) - proteomic studies were only found for two - EAE and CPZ. Additionally, to compare the identified proteoforms in this study with eye diseases (e.g. optic neuritis, dry eye disease, and neuromyelitis optica), these studies were also included (Bai et al., 2009; Jung et al., 2017; Olesen et al., 2019).

Statistical analysis and graphing

Histology and immunohistochemistry data are presented as mean $\pm$ standard error of the mean. Statistical analyses (two-tailed t-test) and graphing of the histological data were performed using GraphPad Prism (version-8; www.graphpad.com, San Diego, CA, USA) software. For proteomic analysis, grey values (i.e. fluorescence intensity) of gel spots were analysed using the unpaired t-test (within Delta 2D software). Significant differences between CPZ and Ctrl groups were considered when $p < 0.05$. Image processing software CorelDRAW (version-2019; www.coreldraw.com, Canada), was used for image assembly in each figure.

Results

Histological changes following CPZ-feeding

Myelin silver staining was used to characterize demyelination in the corpus callosum and components of the visual pathway. The midline corpus callosum was used as a positive control as demyelination in this area is a hallmark of CPZ-feeding (Almuslehi et al., 2020; Sen et al., 2019a). In the Ctrl mice, the corpus callosum was darkly stained indicating normal (intact) myelin sheaths, whereas in CPZ-fed mice, the corpus callosum showed markedly reduced silver staining ($p < 0.0001$) indicating demyelination (Figure 2). Quantitative analysis of the visual pathway revealed no significant demyelination (optic tract, $p < 0.6804$; pretectal nucleus, $p < 0.6099$; lateral geniculate nucleus, $p < 0.9338$ and superior colliculus, $p < 0.8580$) although the effect in the visual cortex was on the cusp of significance ($p < 0.0507$; Figure 2, **Supplementary Figure 1**). Quantitative immunohistochemical analysis of GFAP-positive astrocytes ($p < 0.0002$) and IBA 1-positive microglia ($p < 0.0022$) in the CPZ-fed mice revealed a significant glial activation in the corpus callosum relative to Ctrl mice. No significant changes in GFAP (visual cortex, $p < 0.1894$; optic tract, $p < 0.5723$; pretectal nucleus, $p < 0.8904$; lateral geniculate nucleus, $p < 0.8249$ and superior colliculus, $p < 0.1305$) and IBA 1 (visual cortex, $p < 0.1444$; optic tract, $p < 0.9638$; pretectal nucleus, $p < 0.5998$; lateral geniculate nucleus, $p < 0.7536$ and superior colliculus, $p < 0.2186$) were observed (Figure 2, **Supplementary Figure 2**).

Changes in the optic nerve/tract proteome

A quantitative, high-resolution top-down proteomic analysis was used to assess the optic nerve proteome profile following CPZ-feeding. Optic nerve samples from both Ctrl and CPZ groups produced well-resolved 2DE gels with spots distributed across the full range of pI and MW (Figure 3A). Figure 3A also shows spots (circled green or red) that changed significantly relative to Ctrl in the soluble (SP) and membrane (MP) sub-proteomes (34 spots in total). Comparative image analysis (Ctrl vs CPZ) revealed that 21 MP spots increased in fluorescent volume (i.e. proteoform abundance) whereas in the SP fraction, 7 spots increased and 6 decreased in abundance ($p < 0.05$; Table 1). The average total spot numbers resolved in the MP fractions from Ctrl and CPZ groups were 851 ± 9 and 856 ± 9 , respectively ($n=3$ gels/fraction); the counts for the SP fractions were 929 ± 9 and 925 ± 8 in the Ctrl and CPZ groups, respectively (Figure 3B). Figure 3C illustrates the differences between theoretical and experimental MW (upper panel) and pI (lower panel) of the identified proteoforms. While several proteoforms ($\sim 24\%$) had experimental values for pI and MW comparable to the canonical, theoretical values, the rest varied to differing extents from the identity line, indicating the identification of proteoforms, likely with critical post-translational modifications (e.g. glycosylation, ubiquitination). Collectively,

following CPZ-feeding 79.4% of spots showed increased abundance (in both SP and MP fractions), whereas 20.6% decreased in abundance (**Supplementary Figure 3**). These 34 spots were digested using trypsin, peptides were analysed using LC-TMS, and high-quality hits were obtained (see Table 1).

2DE spots that were 100% reproducible and had significant change in fluorescent volume across technical (n=3) replicates are summarized in Table 1. The top proteoforms from each spot (i.e. first three proteoforms in the identification list bearing the highest scores) were tabulated (Table 1) along with corresponding literature and bioinformatic information (see Methods). The remaining identified proteoforms (i.e. beyond the top three) that satisfied the selection criteria are provided in **Supplementary Table 1**. Of all the resolved spots that changed significantly ($p < 0.05$) in abundance, 70% changed by 1.5-2 fold, 18% by 2.1-3 fold, and 12% by over 3 fold. All identified proteoforms had a ProteinLynx Global Server (PLG) score exceeding 100, with 43% between 100-999, 18% between 1000-1999, 21% between 2000-2999 and 18% exceeding 3000. Similarly, sequence coverage was always $\geq 5\%$ with 5-9% for 6 proteins only, 10-29% for 40 proteins, 30-49% for 27 proteins and $>50\%$ for 11 proteins. Moreover, each identification was based on at least three matched peptides: 38% based on 3-9 peptides, 35% based on 10-19 peptides, 15% based on 20-30 peptides, 7% based on 30-50 peptides and 5% based on over 50 peptides. The combination of high fold change, PLG scores, the greater number of peptides and high sequence coverage indicated high confidence in the spot selection and proteoform identifications.

Table 1
Identified optic nerve/tract proteoforms and comparison with published literature

Spot ID	Response to CPZ (ratio/p-value)	Gene ID	Identified proteoform	Protein accession	Theoretical MW (kDa)/pI	Observed MW (kDa)/pI	PLG Score	Sequence coverage (%)	Matched peptides	Molecular function	Reference CPZ
SP1	(1.57/0.049)↓	Nefm	Neurofilament medium polypeptide	P08553	96.0/4.6	117.3/4.7	3980	48	56	IV	↓Cere (Szila et al., 2020)
		Tubb3	Tubulin beta-3 chain	Q9ERD7	50.9/4.6		2732	37	24	I	-
		Tubb2a	Tubulin beta-2A chain	Q7TMM9	50.3/4.6		2683	46	25	I	-
SP2	(3.58/0.002)↓	Tuba1c	Tubulin alpha-1C chain	P68373	50.6/4.8	110.6/4.9	2548	40	17	I	-
		Tuba1b	Tubulin alpha-1B chain	P05213	50.8/4.8		2511	35	15	I	-
		Tuba1a	Tubulin alpha-1A chain	P68369	50.8/4.8		2511	35	15	I	-
SP3	(2.25/0.05)↓	Serpina3k	Serine protease inhibitor A3K	P07759	47.1/4.8	95.9/4.6	2181	29	14	VII	↓Cere (Szila et al., 2020)
		Serpina3c	Serine protease inhibitor A3C	P29621	46.9/8.0		321	6	6	VII	-
		Serpina3n	Serine protease inhibitor A3N	Q91WP6	46.9/5.5		318	5	4	VII	-
SP4	(1.67/0.001)↑	Hspa4	Heat shock 70 kDa protein 4	Q61316	94.9/5.0	93.5/5.2	2537	45	47	III	-
		Actb	Actin_ cytoplasmic 1	P60710	42.1/5.2		2482	51	26	I	-
		Actg1	Actin_ cytoplasmic 2	P63260	42.1/5.2		2475	47	25	I	-
SP5	(3.12/0.001)↓	Hsp90ab1	Heat shock protein HSP 90-beta	P11499	83.6/4.8	90.8/5.1	639	26	19	III	↓Sple (Partr et al., 2016)
		Hsph1	Heat shock protein 105 kDa	Q61699	97.4/5.2		601	19	18	III	↓Cere (Szila et al., 2020)
		Hsp90aa1	Heat shock protein HSP 90-alpha	P07901	85.2/4.7		555	28	18	III	-

Spot ID	Response to CPZ (ratio/p-value)	Gene ID	Identified proteoform	Protein accession	Theoretical MW (kDa)/pI	Observed MW (kDa)/pI	PLG Score	Sequence coverage (%)	Matched peptides	Molecular function	Reference CPZ
SP6	(2.01/0.038)↓	Mag	Myelin-associated glycoprotein	P20917	70.1/4.9	90.2/4.4	1539	19	12	IV	↓Cere (Wern al., 20
		Hba	Hemoglobin subunit alpha	P01942	15.1/8.6		1312	29	4	VI	-
SP7	(1.59/0.021)↓	Vcp	Transitional endoplasmic reticulum ATPase	Q01853	90.0/4.7	90.1/5.2	2829	53	71	III	-
		Actn4	Alpha-actinin-4	P57780	10.5/5.1		2240	50	56	I	-
		Actn1	Alpha-actinin-1	Q7TPR4	10.4/5.7		1011	35	35	I	-
SP8	(1.67/0.041)↑	Aco2	Aconitate hydratase	Q99KI0	86.2/7.8	87.7/6.8	2217	33	29	II	↑Cere (Sen € 2019€
SP9	(1.72/0.035)↑	Pfkm	ATP-dependent 6-phosphofructokinase	P47857	86.1/7.9	85.5/6.9	561	26	23	II	-
		Aco2	Aconitate hydratase	Q99KI0	86.2/7.8		496	17	13	II	↑Cere (Sen € 2019€
SP10	(1.69/0.037)↑	Syn1	Synapsin-1	O88935	74.2/10.4	77.2/8.5	930	27	13	XI	-
		Map6	Microtubule-associated protein 6	Q7TSJ2	96.7/6.3		247	14	8	I	-
SP11	(1.69/0.015)↑	Chmp4b	Charged multivesicular body protein 4b	Q9D8B3	24.9/4.6	58.4/4.7	2045	42	14	VIII	↓Cere (Sen € 2019€
		Otub1	Ubiquitin thioesterase OTUB1	Q7TQI3	31.5/4.7		1510	29	8	III	-
		Anxa5	Annexin A5	P48036	35.8/4.6		1303	25	11	IX	↑Cere (Wern al., 20 ↓Cere (Szila et al., 2020)
SP12	(2.29/0.015)↑	Sncb	Beta-synuclein	Q91ZZ3	14.1/4.2	27.0/4.6	3031	34	6	III	-
		Snca	Alpha-synuclein	O55042	14.5/4.5		1063	16	4	III	-
SP13	(1.61/0.04)↑	Pvalb	Parvalbumin alpha	P32848	11.9/4.8	17.6/4.9	9188	77	12	V	-

Spot ID	Response to CPZ (ratio/p-value)	Gene ID	Identified proteoform	Protein accession	Theoretical MW (kDa)/pI	Observed MW (kDa)/pI	PLG Score	Sequence coverage (%)	Matched peptides	Molecular function	Refer CPZ
		Txn	Thioredoxin	P10639	12.0/4.6		3687	36	6	V	-
		Sh3bgrl	SH3 domain-binding glutamic acid-rich-like protein	Q9JJU8	12.9/4.7		1747	50	5	V	-
MP1	(2.75/0.01)↑	Nefm	Neurofilament medium polypeptide	P08553	96.0/4.6	132.3/4.7	2693	40	34	IV	↓Cere (Szila et al., 2020)
		Vim	Vimentin	P20152	53.7/4.9		2063	55	31	I	↑Cere (Szila et al., 2020; Werner et al., 2020)
		Tuba3a	Tubulin alpha-3 chain	P05214	50.64/4.8		646	15	6	I	-
MP2	(3.55/0.01)↑	Ina	Alpha-internexin	P46660	55.6/5.2	97.8/4.6	148	5	4	I	-
MP3	(1.63/0.03)↑	Aco2	Aconitate hydratase	Q99KI0	86.2/7.8	90.1/6.9	1278	26	22	II	↑Cere (Sen et al., 2019)
MP4	(2.19/0.03)↑	Tf	Serotransferrin	Q92111	78.9/6.9	82.8/6.8	539	13	12	VI	-
MP5	(1.84/0.02)↑	Atp5f1a	ATP synthase subunit alpha	Q03265	59.9/9.6	66.3/6.8	3951	53	39	II	↑Cere (Sen et al., 2019)
		Cap1	Adenylyl cyclase-associated protein 1	P40124	51.9/7.3		832	31	11	I	-
		Anxa11	Annexin A11	P97384	54.4/7.6		379	25	13	IX	-
MP6	(1.71/0.02)↑	Aldh6a1	Methylmalonate-semialdehyde dehydrogenase	Q9EQ20	58.4/8.1	64.1/6.7	571	30	16	II	-
		Cct4	T-complex protein 1 subunit delta	P80315	58.6/8.0		200	19	12	I	-
		Gpi	Glucose-6-phosphate isomerase	P06745	63.0/8.2		188	20	11	II	-

Spot ID	Response to CPZ (ratio/p-value)	Gene ID	Identified proteoform	Protein accession	Theoretical MW (kDa)/pI	Observed MW (kDa)/pI	PLG Score	Sequence coverage (%)	Matched peptides	Molecular function	Refer CPZ
MP7	(1.51/0.01)↑	Gfap	Glial fibrillary acidic protein	P03995	50.0/5.1	57.7/4.8	25975	87	84	I	↑Cere (Sen et al., 2019; Szilacsi et al., 2020; Werner et al., 2020)
		Nefl	Neurofilament light polypeptide	P08551	61.6/4.4		14009	59	45	IV	↓Cere (Sen et al., 2019; Szilacsi et al., 2020; Werner et al., 2020)
		Pdia6	Protein disulfide-isomerase A6	Q922R8	48.5/4.8		9115	44	22	II	-
MP8	(1.56/0.002)↑	Tuba1b	Tubulin alpha-1B chain	P05213	50.8/4.8	55.9/4.9	3205	33	12	I	-
		Tuba1a	Tubulin alpha-1A chain	P68369	50.8/4.8		3205	33	12	I	-
		Tuba1c	Tubulin alpha-1C chain	P68373	50.6/4.8		3205	38	13	I	-
MP9	(1.66/0.004)↑	Des	Desmin	P31001	53.6/5.0	53.0/4.7	791	13	8	I	-
		Prph	Peripherin	P15331	54.4/5.3		212	11	10	I	-
		Sparc	Secreted protein acidic and cysteine rich	P07214	35.3/4.6		131	8	3	VIII	-
MP10	(1.52/0.001)↑	Nsf1c	NSFL1 cofactor p47	Q9CZ44	40.7/4.9	51.3/4.8	3878	51	20	XI	-
		Actg1	Actin_ cytoplasmic 2	P63260	42.1/5.2		2178	44	23	I	-
		Actb	Actin_ cytoplasmic 1	P60710	42.1/5.2		2178	44	23	I	-
MP11	(1.86/0.007)↑	Idh2	Isocitrate dehydrogenase	P54071	51.7/9.0	50.6/7.0	1103	21	9	II	-
		Uqcrc2	Cytochrome b-c1 complex subunit 2	Q9DB77	48.3/9.7		753	18	10	II	-
		Serpinh1	Heat shock protein 47	P19324	46.6/9.3		413	7	4	III	-
MP12	(1.64/0.02)↑	Cnp	2'-3'-cyclic-nucleotide 3'-phosphodiesterase	P16330	47.5/9.4	49.1/6.6	4642	38	25	II	↓Cere (Szilacsi et al., 2020)

Spot ID	Response to CPZ (ratio/p-value)	Gene ID	Identified proteoform	Protein accession	Theoretical MW (kDa)/pI	Observed MW (kDa)/pI	PLG Score	Sequence coverage (%)	Matched peptides	Molecular function	Refer CPZ
		Paics	Multifunctional protein ADE2	Q9DCL9	47.7/7.0		1028	22	14	II	-
		Psmc5	26S proteasome regulatory subunit 8	P62196	45.8/7.4		587	27	12	III	-
MP13	(2.19/0.001)↑	Cs	Citrate synthase	Q9CZU6	52.0/8.8	48.5/6.6	913	19	9	II	-
		Ckmt1	Creatine kinase U-type	P30275	47.4/8.2		621	23	11	II	↑Cere (Sen et al., 2019)
		Pgk1	Phosphoglycerate kinase 1	P09411	44.9/7.9		317	31	12	II	-
MP14	(2.07/0.02)↑	Pgk2	Phosphoglycerate kinase 2	P09041	45.3/6.4	48.1/6.8	451	14	6	II	-
		Ckmt2	Creatine kinase S-type	Q6P8J7	47.9/8.8		193	7	6	II	-
MP15	(1.68/0.001)↑	Impact	Protein IMPACT	O55091	36.7/4.8	46.3/	268	18	6	I	-
		Rp2	Protein XRP2	Q9EPK2	40.3/4.9	4.8	233	17	6	II	-
		Dpysl2	Dihydropyrimidinase-related protein 2	O08553	62.7/6.0		232	18	9	II	-
MP16	(1.83/0.005)↑	Fbxo2	F-box only protein 2	Q80UW2	34.0/4.0	43.9/4.0	1071	19	5	III	-
MP17	(6.07/0.03)↑	Tpm2	Tropomyosin beta chain	P58774	32.9/4.5	41.5/4.4	3200	49	20	I	-
		Tpm1	Tropomyosin alpha-1 chain	P58771	32.7/4.5		1823	32	15	I	↑Cere (Szila et al., 2020)
		Tpm3	Tropomyosin alpha-3 chain	P21107	33.1/4.5		624	12	6	I	-
MP18	(1.66/0.001)↑	Clta	Clathrin light chain A	O08585	25.7/4.3	40.9/4.6	397	14	6	X	-
MP19	(2.21/0.007)↑	Cyb5a	Cytochrome b5	P56395	15.2/4.8	21.5/4.9	1444	46	5	II	-
		Mylpf	Myosin regulatory light chain 2	P97457	19.1/4.6		552	28	5	I	-
		Vsnl1	Visinin-like protein 1	P62761	22.3/4.8		422	33	8	V	-
MP20	(1.56/0.007)↑	Cox5b	Cytochrome c oxidase subunit 5B	P19536	14.1/8.5	17.5/5.9	1660	21	4	II	-

Spot ID	Response to CPZ (ratio/p-value)	Gene ID	Identified proteoform	Protein accession	Theoretical MW (kDa)/pI	Observed MW (kDa)/pI	PLG Score	Sequence coverage (%)	Matched peptides	Molecular function	Reference CPZ
		Fabp5	Fatty acid-binding protein 5	Q05816	15.5/6.2		997	23	4	XII	-
MP21	(1.65/0.01)↑	Dynl1	Dynein light chain 1	P63168	10.5/7.2	11.2/	3752	15	3	I	-
		Hba	Hemoglobin subunit alpha	P01942	15.1/8.6	6.7	2480	56	8	VI	-
		H4c1	Histone H4	P62806	11.4/11.9		1242	29	3	I	-

Key: SP, soluble protein; MP, membrane protein; MW, molecular weight; pI, isoelectric point; %, percentage; ↑, increase; ↓, decrease; -, not found or investigated; mononuclear cell; CPZ, cuprizone; EAE, experimental autoimmune encephalomyelitis; MS, Multiple Sclerosis; ED, eye disease; ON, optic neuritis; DED, dry eye; studies in the literature identified proteins without describing the magnitude of their change (e.g. fold increase or decrease) compared to controls; thus, these are described as absent in these studies; and therefore, a ↓ sign is used in this table to maintain the consistency with those previous studies. Some spots can be identified as a single proteoform; presented here are the top three hits with the highest score, coverage and peptide count. Additional hits are provided in **Supplementary Table 1**. U, UniProt database. PLG score, sequence coverage, theoretical (MW/pI), and the number of unique peptides were acquired from the PLG. Experimental (MW/pI) resolved in the 2DE gels. Molecular function: I, structural; II, metabolic; III, molecular chaperone; IV, myelin component; V, signalling; VI, iron binding; VII, proteolysis; VIII, endocytosis; IX, exocytosis; X, endocytosis; XI, exocytosis; XII, transportation. References were identified using PubMed searches on CPZ, EAE, and MS, and used to correlate proteoforms with literature.

Literature mining and bioinformatic analysis

A comprehensive literature search was carried out to investigate the linkage of identified proteoforms with MS and its animal models (e.g. EAE and CPZ; Table 1 and Figure 4). Twenty-two percent of the proteoforms identified in this study were previously identified as canonical proteins in other CPZ studies, whereas the remaining 78% were newly identified (i.e. not reported previously in CPZ studies; Table 1). Similarly, 24% of the identified proteoforms were previously reported as canonical proteins in MS studies, whereas the remaining 76% were newly identified relative to the previous MS literature; in ED the previously vs newly identified proteoforms were 5 and 95%, respectively. In EAE, 63% of proteoforms identified here were previously reported as canonical proteins, whereas 37% were newly identified in this study (Table 1). It is thus however critical to emphasize the identification of specific proteoforms using the top-down analytical approach rather than only reporting canonical amino acid sequences that represent any myriad of possible proteoforms.

Subcellular localization analysis using UniProt revealed that 34% and 31% of the identified proteoforms are identified as cytoplasmic and cytoskeletal, respectively; 14% and 13% of the proteoforms are, respectively, mitochondrial and nuclear, and a small fraction (1-3%) are found in endoplasmic reticulum, axon, Golgi apparatus and melanosomes (Figure 4A). Protein class analysis using PANTHER revealed that 26% of proteoforms are involved in metabolic and/or cytoskeletal processes (Figure 4B). In addition, other proteoforms are implicated in different molecular functions including protein-binding activity modulators (11%), membrane trafficking (9%), protein modifying enzymes (7%), calcium-binding (5%) and chaperones (6%). A small percentage (2%) of proteoforms function in cell adhesion, transportation, extracellular matrix, intercellular signalling, and transmembrane signalling. Furthermore, biological process analysis using PANTHER showed that the majority of the proteoforms were involved in cellular (31%), metabolic (18%), and organization/regulatory (26%) processes (Figure 4C). Moreover, the literature search indicated various molecular functions of the identified proteoforms including structural (36%), metabolic (24%), chaperone (15%), and signalling or myelin components (5% each; Figure 4D). Protein-protein interaction using STRING revealed a central role of structural proteoforms having strong interactions with metabolic, chaperone, signalling, and myelin proteoforms, among others (Figure 4E). The STRING analysis showed that there are direct connections between ~90% of proteoforms with the exception of seven (microtubule-associated protein 6, protein IMPACT, cytochrome b5, methylmalonate-semialdehyde dehydrogenase, protein XRP2, hemoglobin subunit alpha, and charged multivesicular body protein 4b) that are not linked in any obvious direct manner. The major identified interactions were between the structural proteoforms; 21 of the 23 identified structural proteoforms have well-established interactions. Interestingly, three different clusters of interactions were observed among actin, tubulin, and tropomyosin; notably, some of these cytoskeletal proteoforms appear to leave the SP fraction and move to the MP sub-proteome due to the CPZ treatment. In addition, an association of the identified chaperone proteoforms, including heat shock protein family, ubiquitin thioesterase, and synuclein, was also indicated by the STRING analysis. Metabolic and mitochondrial regulating proteoforms constituted another network with aconitate hydratase, citrate synthase, phosphoglycerate kinase, and creatine kinase.

Discussion

This study used 0.1% CPZ-feeding for 12 weeks in young adult C57Bl/6 mice to investigate whether a slow and progressive degenerative process can induce histological and proteomic alterations in the axonal tracts and nuclear components of the visual pathway. Although histological changes such as demyelination and glial activation were evident in the corpus callosum, none of these changes were observed in the components of visual pathway. However, multiple alterations in the optic nerve/tract proteome were detected using a sensitive, well-established, quantitative top-down proteomic analysis. Subsequent comprehensive literature and bioinformatic analyses revealed that many of the proteoforms identified in the soluble and membrane sub-proteomes of the optic nerve/tract are involved in structural and metabolic functions. Likely aggregation/oligomerization of some proteoforms was also detected.

Limited histological changes

Demyelination and inflammation in the components of the visual pathway (e.g. visual cortex, pretectal nucleus, lateral geniculate nucleus, superior colliculus, optic tract) are associated with optic neuritis (Martínez-Lapiscina et al., 2014; Sapienza et al., 2016) and these conditions have been investigated in animal studies (Guido, 2018; Huberman and Niell, 2011; Seabrook et al., 2017). In a previous study, we found significant demyelination and gliosis in the visual cortex when mice were fed with 0.2% CPZ for 5 weeks, but not in the optic tract (Sen et al., 2020b). In the current study, the lack of detectable demyelination in the visual cortex might be attributable to the staining method or to the concentration of CPZ used. For example, Nile Red staining detected changes in the myelin components of the corpus callosum following only two days of CPZ-feeding, whereas other traditional histological staining methods (e.g. silver, or Luxol-fast blue) detected quantifiable demyelination only after 4-5 weeks (Hiremath et al., 1998; Sen et al., 2020b; Teo et al., 2021). Additionally, demyelination has been detected in the optic nerve after 12 weeks of CPZ-feeding, but no other part of the visual pathway was assessed in that study (Namekata et al., 2014). In the current study, 0.1% CPZ-feeding was extended to 12 weeks to analyse demyelination and gliosis in optic tract, visual cortex, pretectal nucleus, lateral geniculate nucleus, and superior colliculus under the conditions of a slow, progressive demyelination that is more reminiscent of MS. While demyelination and gliosis in the corpus callosum were observed, no significant changes occurred in any of the nuclei associated with the visual pathway, consistent with previous work by Taveggia et al. (2008). In addition, the temporal response of CPZ may be due to the differential expression profiles of oligodendrocytes in different CNS regions (Butt et al., 1995). For example, mice haplo-insufficient for type III neuregulin-1 (a growth factor that promotes oligodendrocyte and Schwann cell development) showed less myelination in the corpus callosum but no effect on the optic nerve and spinal cord, indicating regional differences in the regulation of oligodendrocyte function (Taveggia et al., 2008). Whether these factors (e.g. neuregulin-1 expression) lead to the heterogeneity of oligodendrocyte distribution in the brain vs spinal cord or in optic nerve (Ornelas et al., 2016), as well as in the response to CPZ, remains untested.

Marked proteomic changes

Demyelination in the optic nerves of MS patients is inferred by changes in visual evoked potentials (Barton et al., 2019; Langwińska-Wośko et al., 2012; Leocani et al., 2018), although early changes (i.e. subtle alterations in vision) are not reported in the clinic until after an MS diagnosis has already been made. Increased abundance of inflammatory cytokines (e.g. tumour necrosis factor- α) and the axonal marker neurofilament light chain in the cerebrospinal fluid (CSF) have been proposed as early biomarkers to diagnose MS and/or optic neuritis in patients (Olesen et al., 2019). In addition, these markers could also then be considered as pre-symptomatic/early indicators of MS risk, since optic neuritis patients often go on to develop MS (Costello, 2016; Kale, 2016). However, there exist issues with these and other canonical proteins identified to date with regard to their capacity to serve as selective biomarkers for MS (Sen et al., 2021).

In this study, optic nerve/tract tissue was used to investigate whether CPZ-induced changes in the proteomic profile could lead to the identification of candidate proteoform biomarkers and/or some indication of initiating pathological mechanism(s). Top-down proteomic analysis revealed changes in the abundance of at least 75 proteoforms (Table 1) in the optic nerve/tract tissue, using stringent criteria to ensure only the most robust identifications. To understand the function of these proteoforms and their relevance to demyelinating CNS conditions such as MS or its animal models, a comprehensive literature search was carried out using the PubMed search engine. The optic nerve/tract proteome changes identified indicate a substantial similarity with those previously identified in EAE studies (Table 1). In part, this similarity is likely attributable to the large number (15) of proteomic studies carried out using the EAE model (Alt et al., 2005; Dagley et al., 2014; Farias et al., 2012; Fazeli et al., 2013; Fazeli et al., 2010; Gonzalez et al., 2019; Hasan et al., 2019; Jain et al., 2009; Jain et al., 2012; Jastorff et al., 2009; Linker et al., 2009; Liu et al., 2007; Raphael et al., 2017; Stoop et al., 2012; Vanheel et al., 2012), whereas only 6 studies used the CPZ model (Martin et al., 2018; Oveland et al., 2018; Partridge et al., 2016; Sen et al., 2019a; Szilagyi et al., 2020; Werner et al., 2010). Importantly, none of these studies investigated the optic nerve/tract proteome but used various other biological samples including CSF, brain, spinal cord and tears. Thus, the current study is the first to investigate changes in the optic nerve/tract proteome. Although not directly comparable, the proteomic changes found here did in part overlap with previously identified changes in the abundance of certain canonical proteins; the major difference here was that use of a top-down approach enabled resolution and identification of critical proteoforms. Thus, several of the proteoform changes in optic nerve/tract correlated with canonical protein changes previously seen in other samples, including cerebellum (Hasan et al., 2019), spinal cord (Fazeli et al., 2013), CSF (Liu et al., 2009), tears (Salvisberg et al., 2014), and blood, reported in CPZ, EAE and MS studies (Berge et al., 2019; Partridge et al., 2016; Raphael et al., 2017). Notably, by separately analysing the soluble and membrane sub-proteomes, and assessing proteoforms rather than canonical proteins, we have been able to gain more detailed information not available in previous studies. For example, neurofilament medium chain was found to increase in abundance in cerebral tissue from mice fed with 0.2% CPZ (Szilagyi et al., 2020) and spinal cord from EAE mice (Farias et al., 2012; Hasan et al., 2019); the data here conclusively identify a decrease of one proteoform in the SP fraction of the optic nerve/tract tissue but a corresponding larger increase in a distinctly different proteoform in the MP sub-proteome (Table 1). While this clearly highlights the essential need to resolve and identify critical proteoforms rather than canonical protein sequences, as well as the potentially serious ramifications of not doing so, the findings may also indicate differential expression/abundance of neurofilament isoforms among different CNS regions, as likely already seen in the hippocampus and cortex (Mesulam and Geula, 1991; Nakamura et al., 1992). Moreover, Szilagyi et al. (2020) fed 8-week male C57Bl/6 mice 0.2% CPZ for four-weeks (samples analysed at 12 weeks), whereas in the current study, mice were fed 0.1% CPZ for 12 weeks, suggesting that prolonged feeding of CPZ may alter the abundance and localization of different neurofilament proteoforms. Furthermore, two other studies (Farias et al., 2012; Hasan et al., 2019) used spinal cord from EAE mice suggesting that differential disease induction (autoimmune in EAE vs metabolic changes in CPZ) may also alter the abundance of neurofilament proteoforms in the CNS. Notably, an increase of neurofilament light chain in serum has been considered as a potential pre-symptomatic biomarker of neurodegeneration in MS (Bjornevik et al., 2019; Varhaug et al., 2019); however, comparable changes also appear in other neurodegenerative disorders as well as in cases of neurotrauma raising questions as to the selectivity of this as a biomarker for MS, unless specific proteoforms are found to be altered in the different conditions (Sen et al., 2021).

Previous MS proteomic studies identified an increase in the abundance of heat shock protein 90-beta (HSP90 β) in tears (Salvisberg et al., 2014) and in peripheral blood mononuclear cells (De Masi et al., 2009). However, neither of these studies provided evidence of full length, intact species. On the contrary, the current study identified a reduction of HSP90 β in the optic nerve tissue. Perhaps the increased abundance of heat shock protein in tears and the circulation is a breakdown product of HSP90 β from other CNS regions such as the optic nerve. This may lead to a reduction in the abundance of HSP90 β in the optic nerve

as observed in the current study. Of note, HSP90 β exerts two potential neuroprotective roles in the CNS tissue: firstly, it prevents protein misfolding and aggregation by its chaperone activity and secondly, it inhibits multiple steps in the apoptosis process (Didonna and Opal, 2019; Lanneau et al., 2007; Mosser and Morimoto, 2004). In MS patients, these proteins (or, likely, proteoforms thereof) are overexpressed in neuronal cells and oligodendrocytes around demyelinated lesions, seemingly to protect these cells from degeneration (Cwiklinska et al., 2010; Turturici et al., 2014). Other possible reasons for the differences in the trends of protein abundance is the use of different analytical techniques, experimental model or sample analysed. For example, Szilagyi et al. (2020) and Hasan et al. (2019), respectively, used two different labelling variations of bottom-up proteomic analysis; one identified ~190 canonical proteins that appeared to change in abundance in the corpus callosum of CPZ-fed mice (Szilagyi et al., 2020), while the other identified ~1900 canonical protein changes in CNS samples from EAE mice (Hasan et al., 2019). In contrast, Farias et al. (2012) used a top-down (2DE) proteomic approach with spinal cords from EAE mice and identified alterations in 35 proteoforms (although only theoretical MW and *pI* were reported). Using tear samples from MS patients, Salvisberg et al. (2014) identified 42 canonical proteins differing in abundance between MS and control patients. Thus, as is often the case, bottom-up (i.e. shotgun) studies detected more apparent changes in the abundance of canonical proteins relative to proteome changes identified using a top-down (2DE) approach (De Masi et al., 2009; Farias et al., 2012; Hasan et al., 2019; Salvisberg et al., 2014; Szilagyi et al., 2020). Does this imply differences in sensitivity of the methods? This seems unlikely as bottom-up peptide analysis generally uses less stringent sequence coverage than top-down, and only identifies canonical proteins by inference to amino acid sequences. Therefore, comparable to its correlate transcriptomics, the identification of a large number of potential canonical proteins is expected using the bottom-up method. In contrast, the top-down approach uses more stringent criteria to detect changes in intact *proteoforms* (i.e. a more selective analysis). Therefore, top-down is likely to yield more reliable and focused data (i.e. changes in abundance of relevant species rather than total changes in a canonical protein sequence that likely represents many dozens of proteoforms) (Aebersold et al., 2018; Coorsen and Yergey, 2015; Oliveira et al., 2014; Zhan et al., 2019). Thus, the likelihood of identifying a critical change relevant to underlying molecular mechanisms or the identification of a highly selective biomarker lies in the routine, high-resolution assessment of proteoforms (Sen et al., 2021). Our previous detailed review of proteomic studies into MS found that at least nine proteoforms (of septin, tubulin, complement, glial fibrillary acidic protein, protein disulfide isomerase, calreticulin, hexokinase, aconitate hydratase and dynamin 1) consistently changed in abundance in both MS and animal models (Sen et al., 2021). Of these, five proteoforms (of septin, glial fibrillary acidic protein, aconitate hydratase, protein disulfide isomerase and tubulin) were also identified in the current study - suggesting that these may be potential early biomarkers. Opposite trends in abundance (i.e. increase or decrease) in different biological samples may also be attributed to the differential expression of proteins and distribution of proteoforms in these different samples, which depend on tissue function and the magnitude of pathological changes. For example, the spinal cords of EAE mice (i.e. the most pathologically affected CNS region in EAE) showed changes in the abundance of 1357 (uncategorised proteins were not considered) canonical proteins whereas only ~50 protein changes were found in brain stem and cerebellum (Hasan et al., 2019). The literature search was thus extended to include proteome changes in eye disorders to investigate their potential relevance to optic nerve/tract proteomic changes in CPZ-fed mice. Only three identifications (transitional endoplasmic reticulum ATPase, neurofilament light polypeptide and haemoglobin subunit alpha) were consistent with those reported in CSF samples from neuromyelitis optica (Bai et al., 2009) and optic neuritis (Olesen et al., 2019), and in tear samples from patients with dry eye disease (Jung et al., 2017). These findings suggest a link between eye diseases and the CPZ-induced optic nerve/tract proteome changes that requires further study, particularly with regard to likely early changes prior to an MS diagnosis.

Aggregation and oligomerisation proteoforms

The current study detected changes in 12 molecular chaperone proteoforms (Table 1). These changes are not unique to optic nerve/tract as they were reported previously in other CPZ (Partridge et al., 2016; Szilagyi et al., 2020), EAE (Hasan et al., 2019; Jain et al., 2012; Vanheel et al., 2012) and MS studies (De Masi et al., 2009; Salvisberg et al., 2014). Decreased molecular chaperone proteoforms have been linked to protein aggregation (Ciechanover and Kwon, 2017; Liberek et al., 2008), which can contribute to neurodegeneration and demyelination associated with human degenerative diseases (David and Tayebi, 2014; Soto and Pritzkow, 2018). It has been shown that the increased expression of chaperones (e.g. heat shock proteins) in astrocytes and neurons inhibits apoptosis of these cells in rat spinal cord (Chang et al., 2014). Moreover, optic nerve regeneration and retinal ganglion cell survival in zebrafish was promoted by HSP70 and these processes were reduced when the HSP70 was inhibited (Nagashima et al., 2011). Another study demonstrated that neurite growth of rat retinal cells increased following application of exogenous HSP α B-crystallin (Wang et al., 2012). Chaperones also modulate the cytoskeleton of neuronal cells and mediate their regeneration via enhancing intermediate filament assembly (Hirata et al., 2003). These observations indicate that the increased abundance of some chaperone proteoforms (e.g. HSP 70 kDa and HSP 47 kDa) in the present study could reflect the demands for these in the optic nerve/tract in order to reduce structural deformities and protect or regenerate neuronal tissue injured by CPZ exposure.

We (Sen et al., 2019a) and others (Liu et al., 2009) have found evidence of homo-oligomerization of proteoforms. The current data also suggest oligomerization (e.g. an approximate doubling of molecular weight; Table 1) of some species such as tubulin α -1C chain (50.6 kDa monomer vs 110.6 kDa experimentally observed), serine protease inhibitor A3K (47.1 kDa vs 95.9 kDa), beta-synuclein (14.1 vs 27.0) and charged multivesicular body protein 4b (24.9 kDa vs 58.4 kDa). While oligomerization of tubulin α -1C chain, serine protease inhibitor A3K, beta-synuclein or charged multivesicular body protein 4b have not previously been identified in CPZ-fed mice, earlier studies have observed that these proteins do indeed oligomerize (Carrell et al., 2008; Mozziconacci et al., 2008). Notable in the case of beta-synuclein is that it forms hetero-oligomers with alpha-synuclein, and these were found together in the ~27kDa spot (SP12, Table 1). Oligomerization of proteins can lead to the proteins aggregation which is argued to be the cause of many neurological diseases including MS (David and Tayebi, 2014; Michaels et al., 2015). In addition, gel shifts in MW and *pI* relative to theoretical values (i.e. of the amino acid sequence only) were also observed for some of the identified species (Table 1, Figure 3C) such as neurofilament medium polypeptide (96.0/4.6 vs 117.3/4.7), myelin-associated glycoprotein (70.1/4.9 vs 90.2/4.4), ATP synthase subunit alpha (59.9/9.6 vs 66.3/6.8), cytochrome c oxidase subunit 5B (14.1/8.5 vs 17.5/5.9), consistent with post-translational modifications and thus the identification of select proteoforms (Rabilloud and Lelong, 2011; Sen et al., 2019a).

Structural proteoforms

In the current study, major changes in cytoskeleton proteoforms such as actin and tubulin were detected in the optic nerve/tract. The alterations of these structural proteoforms in this slow progressive demyelinating model may reflect early changes in cellular structure as a result of CPZ-feeding. Importantly, the

present study identified an increase in the abundance of intermediate filament proteins such as glial fibrillary acidic protein and vimentin, suggesting that astrocytes are activated in the optic nerve/tract (Sofroniew and Vinters, 2010). However, histological examination of glial fibrillary acidic protein in the optic tract did not detect any significant difference in glial staining intensity relative to the Ctrl group. This suggests that 2DE is more sensitive in revealing early *proteoform* changes, perhaps due in part to the larger amount of sample analysed relative to tissue sections. These proteomic data are thus indicative of notable structural disturbances in the optic nerve/tract following CPZ-feeding that might contribute to conditions such as MS (Love, 2006).

Notably, actin and tubulin are often used as 'house-keeping' loading controls in assays such as western blots, in the very risky and unfounded hope that they do not change under the conditions of the experiment (Zhang et al., 2012). The marked changes in abundance of these structural *proteoforms* in the current study argue strongly against this practise and are consistent with other reports cautioning against this (Eaton et al., 2013; Nie et al., 2017). Changes in the abundance of such inappropriately named 'house-keeping' proteins have also been shown in other proteomic studies, including CPZ (Sen et al., 2019a; Werner et al., 2010), EAE (Farias et al., 2012; Fazeli et al., 2010; Hasan et al., 2019) and MS (De Masi et al., 2009; Dumont et al., 2004; Hammack et al., 2004; Liu et al., 2009). Therefore, total protein concentrations must be assessed in each sample and equal concentrations used for analysis (Almuslehi et al., 2020; Hu et al., 2016; Noaman and Coorssen, 2018; Sen et al., 2019a).

Metabolic proteoforms

Another key finding in this study was the detection of changes in the abundance of numerous *proteoforms* associated with metabolic and mitochondrial functions in the optic nerves/tracts. Metabolic dysregulation can lead to demyelination in the CPZ model (Caprariello et al., 2018; Sen et al., 2019a; Teo et al., 2021; Werner et al., 2010), and is thus hypothesized as an early dysfunction leading to MS. Despite finding changes in metabolic *proteoforms*, no demyelination was detected in the optic nerve/tract. This may be attributed to the highly compact myelin structure in the optic nerve tissue which increased the intensity of silver staining (i.e. resulting in saturation) and thus may have limited the detection of demyelination (Sen et al., 2020a). This interpretation is supported by observations in the diphtheria toxin model, in which alterations in axonal structure were observed by ultrastructural analysis despite no overt demyelination (Pohl et al., 2011). Likewise, reduction of myelin basic protein in the optic nerve may result from metabolic turnover (Namekata et al., 2014). Previously, we reported that ~50% of *proteoforms* that changed in abundance in whole brain samples were metabolic (Sen et al., 2019a) whereas here, in the optic nerve/tract, metabolic *proteoforms* constituted only ~24%. Although an indirect comparison, this suggests less metabolic disturbance in the optic nerve/tract tissue relative to the brain, and thus demyelination is readily evident in the corpus callosum but not in the optic nerve/tract. Additional proteomic studies are thus required for direct comparison (optic nerve/tract vs corpus callosum) to investigate the threshold of changes in metabolic *proteoforms* that are necessary for demyelination in optic nerve.

It might be argued that the dosage of CPZ (e.g. 0.2 vs. 0.1%) plays a significant role in changing the profile of metabolic proteins. This seems less likely since a comparable level of demyelination occurred by feeding mice with 0.2% CPZ for 5 weeks or with 0.1% for 12 weeks (Sen et al., 2019a). Likewise, feeding mice with either 0.1% or 0.2% CPZ for 2 weeks yielded comparable demyelination and glial activation in the corpus callosum (Almuslehi et al., 2020). Therefore, it is expected that changes in the abundance of metabolic *proteoforms* in the optic nerve/tract following 0.1% CPZ-feeding for 12 weeks may be comparable to those seen in 0.2% CPZ-feeding for 5 weeks. Nonetheless, this does not rule out progressive but localized effects of CPZ in different areas of the CNS (including the optic nerve/tract). This study also detected changes in six *proteoforms* identified in our previous proteomic analysis of brain (i.e. creatine kinase U-type, neurofilament light polypeptide, glial fibrillary acidic protein, ATP synthase subunit alpha, aconitate hydratase, charged multivesicular body protein 4b) (Sen et al., 2019a). Among these, only 3 (creatine kinase U-type, ATP synthase subunit alpha and aconitate hydratase) are recognized to be directly involved in metabolism. Creatin kinase exerts a variety of bioenergetic and neuroprotective properties in CNS and retinal neurons including buffering and stabilization of intracellular energy reserves, neutralizing calcium ion fluxes, inhibition of mitochondrial permeability, and counteracting intracellular oxidative stress (Beal, 2011; Sia et al., 2019). ATP synthase subunit expression is upregulated during ocular hypertension and it is associated with increased ATP concentration in the retinal ganglion of rats (Kanamoto et al., 2019). An *in vivo* study showed that aconitate hydratase activity increased in optic nerve tissue one day following traumatic injury (Cummins et al., 2013). According to these observations, the increased abundance of creatine kinase U-type, ATP synthase subunit alpha and aconitate hydratase in the optic nerve/tract following CPZ-feeding is indicative of mitochondrial dysregulation. The main cluster of protein-protein interactions in our previous study was identified as metabolic (with malate dehydrogenase, succinate dehydrogenase, aspartate aminotransferase and oxoglutarate dehydrogenase protein (Sen et al., 2019a)), whereas these *proteoforms* were not identified in the current work. This suggests that minimal changes in the complement of *proteoforms*, and their interaction with key metabolic *proteoforms* (e.g. malate dehydrogenase, aconitate hydratase), are required to initiate metabolic disturbances that can induce downstream effects (e.g. demyelination of optic nerve/tract) in the CPZ-fed mice.

Biological functions and interactions

Importantly, from the bioinformatic (UniProt, PANTHER and STRING) and literature (PubMed) analyses, complex linkages among identified *proteoforms* were indicated (Figure 4). For example, the literature search linked *proteoforms* to diverse functions including structural, metabolic, and axonal, suggesting CPZ-induced changes at multiple functional levels. Characterizing such potential interactions is important to understanding the underlying dysregulation of biological processes (Berggard et al., 2007; Sen et al., 2019a). Previous studies have shown that 50-80% of proteins undergo protein-protein interactions (Asgarov et al., 2021; Berggard et al., 2007; Dagley et al., 2014; Sen et al., 2019a). These observations are consistent with the idea that while proteins/*proteoforms* function as monomers, they also interact to form complexes in order to exert their molecular actions (Berggard et al., 2007; De Las Rivas and Fontanillo, 2010; Keskin et al., 2016; Sen et al., 2019a). Consistent with these observations, the current data suggest that ~90% of the identified *proteoforms* were interconnected, indicating molecular cross-talk (Asgarov et al., 2021; Sen et al., 2019a). For example, myelin-associated glycoprotein, a molecule located in the axonal plasmalemma (inner aspect of the myelin sheath) of oligodendrocytes, is said to interact with axonal neurofilament microtubule proteins, leading to phosphorylation of neurofilament microtubules and modulation of axonal diameter (Nguyen et al., 2009). Another example is alpha-internexin, a neuronal protein implicated in neurodegenerative diseases, that cannot exert its effects independently but functions in association with other neurofilament proteins such as neurofilament medium chain, and this interaction is necessary for the axonal transport of neurofilament medium chain in

CNS and optic nerve axons (Yuan et al., 2006). Overall, the protein-protein interaction analysis suggested that alterations in the abundance of the identified proteoforms in optic nerve/tract are likely interrupting molecular cross-talk amongst these species, thereby disrupting associated biochemical reactions and perhaps thereby contributing to disorders such as MS.

Limitations and future work

Despite our best efforts to minimize the experimental variables, we acknowledge certain drawbacks in the current study. Firstly, since 0.2% CPZ-feeding for 12 weeks can reduce visual function in mice (tested using multifocal electroretinograms (Namekata et al., 2014)), it would be important to correlate molecular changes with visual status in future studies. Secondly, this study relied on only one time point (i.e. 12 weeks) of CPZ-feeding. Therefore, future studies should use a temporal analysis to determine the earliest point at which proteoform changes occur as they may identify the triggers for the cascade of molecular alterations that we identified here after 12 weeks of slow demyelination. Finally, the bioinformatic analyses employed (e.g. PANTHER, STRING) are based primarily on literature reports concerning canonical proteins rather than specific proteoforms or oligomers, and this may also influence interpretation of the data in terms of canonical versus actual proteoform changes.

Conclusions

This study was designed to investigate the effects on the visual pathway of a CPZ-feeding paradigm producing a slow, progressive demyelination, using both histological and proteomic analyses. While no significant histological changes were identified, the data established marked optic nerve/tract proteome dysregulation, which may assist in understanding molecular/cellular alterations that are linked to demyelinating conditions. The data highlight the importance of using top-down proteomic analyses in resolving key early proteoform changes as these seem likely to precede demyelination and glial activation. Furthermore, this detailed investigation (histology, proteomics, bioinformatics and literature mining) provides further insight into the regionally differential effects of CPZ on the CNS. Additionally, the current dataset serves as a baseline for changes in the optic nerve/tract proteome of the CPZ model, in support of future studies.

Declarations

ETHICAL STATEMENT

Ethics approval and consent to participate

Research and animal care procedures were approved by the animal ethics committee of Western Sydney University (ethics approval number A10394) in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (8th edition) as laid out by the National Health and Medical Research Council of Australia.

Consent for publication

Not applicable

Availability of data and materials

All data generated or analysed during this study are provided inside the manuscript and electronic supplementary information files.

Competing interests:

The authors declare no conflicts of interest.

Funding:

This study was funded by the Rotary Club of Narellan (grant number: Not applicable).

Authors' contributions:

MSMA and MKS carried out the lab work, data analysis, and wrote the first draft of the manuscript. All authors participated in the study design, reviewed the data, edited, and approved the final version of the manuscript.

Acknowledgements:

The authors acknowledge the Western Sydney University School of Medicine Animal Care and Mass Spectrometry Facilities for their help with this project.

Authors' information:

Not applicable

References

1. Aebersold, R., J.N. Agar, I.J. Amster, M.S. Baker, C.R. Bertozzi, E.S. Boja, C.E. Costello, B.F. Cravatt, C. Fenselau, B.A. Garcia, Y. Ge, J. Gunawardena, R.C. Hendrickson, P.J. Hergenrother, C.G. Huber, A.R. Ivanov, O.N. Jensen, M.C. Jewett, N.L. Kelleher, L.L. Kiessling, N.J. Krogan, M.R. Larsen, J.A. Loo, R.R. Ogorzalek Loo, E. Lundberg, M.J. MacCoss, P. Mallick, V.K. Mootha, M. Mrksich, T.W. Muir, S.M. Patrie, J.J. Pesavento, S.J. Pitteri, H. Rodriguez, A. Saghatelian, W. Sandoval, H. Schlüter, S. Sechi, S.A. Slavoff, L.M. Smith, M.P. Snyder, P.M. Thomas, M. Uhlén, J.E. Van Eyk, M. Vidal, D.R. Walt, F.M. White, E.R. Williams, T. Wohlschläger, V.H. Wysocki, N.A. Yates, N.L. Young, and B. Zhang. 2018. How many human proteoforms are there? *Nature Chemical Biology*. 14:206-214.
2. Almuslehi, M.S., M.K. Sen, P.J. Shortland, D.A. Mahns, and J.R. Coorssen. 2020. CD8 T-cell Recruitment Into the Central Nervous System of Cuprizone-Fed Mice: Relevance to Modeling the Etiology of Multiple Sclerosis. *Frontiers in Cellular Neuroscience*. 14:43.
3. Alt, C., K. Duvefelt, B. Franzen, Y. Yang, and B. Engelhardt. 2005. Gene and protein expression profiling of the microvascular compartment in experimental autoimmune encephalomyelitis in C57Bl/6 and SJL mice. *Brain Pathol.* 15:1-16.
4. Araujo, S.E.S., H.R. Mendonca, N.A. Wheeler, P. Campello-Costa, K.M. Jacobs, F.C.A. Gomes, M.A. Fox, and B. Fuss. 2017. Inflammatory demyelination alters subcortical visual circuits. *J Neuroinflammation*. 14:162.
5. Asgarov, R., M.K. Sen, M. Mikhael, T. Karl, E. Gyengesi, D.A. Mahns, C.S. Malladi, and G.W. Münch. 2021. Characterisation of the Mouse Cerebellar Proteome in the GFAP-IL6 Model of Chronic Neuroinflammation. *The Cerebellum*.
6. Athappilly, G., V.S. Pelak, N. Mandava, and J.L. Bennett. 2008. Ischemic optic neuropathy. *Neurol Res*. 30:794-800.
7. Bai, S., S. Liu, X. Guo, Z. Qin, B. Wang, X. Li, Y. Qin, and Y.H. Liu. 2009. Proteome analysis of biomarkers in the cerebrospinal fluid of neuromyelitis optica patients. *Molecular vision*. 15:1638-1648.
8. Barton, J.L., J.Y. Garber, A. Klistorner, and M.H. Barnett. 2019. The electrophysiological assessment of visual function in Multiple Sclerosis. *Clinical neurophysiology practice*. 4:90-96.
9. Beal, M.F. 2011. Neuroprotective effects of creatine. *Amino acids*. 40:1305-1313.
10. Berge, T., A. Eriksson, I.S. Brorson, E.A. Hogestol, P. Berg-Hansen, A. Doskeland, O. Mjaavatten, S.D. Bos, H.F. Harbo, and F. Berven. 2019. Quantitative proteomic analyses of CD4(+) and CD8(+) T cells reveal differentially expressed proteins in multiple sclerosis patients and healthy controls. *Clin Proteomics*. 16:19.
11. Berggard, T., S. Linse, and P. James. 2007. Methods for the detection and analysis of protein-protein interactions. *Proteomics*. 7:2833-2842.
12. Bjornevik, K., K.L. Munger, M. Cortese, C. Barro, B.C. Healy, D.W. Niebuhr, A.I. Scher, J. Kuhle, and A. Ascherio. 2019. Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis. *JAMA neurology*:e193238.
13. Broadwater, L., A. Pandit, R. Clements, S. Azzam, J. Vadnal, M. Sulak, V.W. Yong, E.J. Freeman, R.B. Gregory, and J. McDonough. 2011. Analysis of the mitochondrial proteome in multiple sclerosis cortex. *Biochim Biophys Acta*. 1812:630-641.
14. Butt, A.M., M. Ibrahim, F.M. Ruge, and M. Berry. 1995. Biochemical subtypes of oligodendrocyte in the anterior medullary velum of the rat as revealed by the monoclonal antibody Rip. *Glia*. 14:185-197.
15. Butt, R.H., and J.R. Coorssen. 2005. Postfractionation for enhanced proteomic analyses: routine electrophoretic methods increase the resolution of standard 2D-PAGE. *J Proteome Res*. 4:982-991.
16. Butt, R.H., and J.R. Coorssen. 2013. Coomassie blue as a near-infrared fluorescent stain: a systematic comparison with Sypro Ruby for in-gel protein detection. *Mol Cell Proteomics*. 12:3834-3850.
17. Capriariello, A.V., J.A. Rogers, M.L. Morgan, V. Hoghooghi, J.R. Plemel, A. Koebel, S. Tsutsui, J.F. Dunn, L.P. Kotra, S.S. Ousman, V. Wee Yong, and P.K. Stys. 2018. Biochemically altered myelin triggers autoimmune demyelination. *Proc Natl Acad Sci U S A*. 115:5528-5533.
18. Carrell, R.W., A. Mushunje, and A. Zhou. 2008. Serpins show structural basis for oligomer toxicity and amyloid ubiquity. *FEBS letters*. 582:2537-2541.
19. Chang, C.-K., W. Chou, H.-J. Lin, Y.-C. Huang, L.-Y. Tang, M.-T. Lin, and C.-P. Chang. 2014. Exercise preconditioning protects against spinal cord injury in rats by upregulating neuronal and astroglial heat shock protein 72. *International journal of molecular sciences*. 15:19018-19036.
20. Ciechanover, A., and Y.T. Kwon. 2017. Protein Quality Control by Molecular Chaperones in Neurodegeneration. *Frontiers in neuroscience*. 11:185.
21. Colligris, P., M.J. Perez de Lara, B. Colligris, and J. Pintor. 2018. Ocular manifestations of Alzheimer's and other neurodegenerative diseases: the prospect of the eye as a tool for the early diagnosis of Alzheimer's disease. *Journal of ophthalmology*. 2018.
22. Coorssen, J.R., and A.L. Yergey. 2015. Proteomics Is Analytical Chemistry: Fitness-for-Purpose in the Application of Top-Down and Bottom-Up Analyses. *Proteomes*. 3:440-453.
23. Costello, F. 2016. Vision Disturbances in Multiple Sclerosis. *Semin Neurol*. 36:185-195.
24. Cummins, N., C.A. Bartlett, M. Archer, E. Bartlett, J.M. Hemmi, A.R. Harvey, S.A. Dunlop, and M. Fitzgerald. 2013. Changes to mitochondrial ultrastructure in optic nerve vulnerable to secondary degeneration in vivo are limited by irradiation at 670 nm. *BMC neuroscience*. 14:98.
25. Cwiklinska, H., M.P. Mycko, B. Szymanska, M. Matysiak, and K.W. Selmaj. 2010. Aberrant stress-induced Hsp70 expression in immune cells in multiple sclerosis. *Journal of neuroscience research*. 88:3102-3110.
26. Dagley, L.F., N.P. Croft, R. Isserlin, J.B. Olsen, V. Fong, A. Emili, and A.W. Purcell. 2014. Discovery of novel disease-specific and membrane-associated candidate markers in a mouse model of multiple sclerosis. *Mol Cell Proteomics*. 13:679-700.
27. David, M.A., and M. Tayebi. 2014. Detection of Protein Aggregates in Brain and Cerebrospinal Fluid Derived from Multiple Sclerosis Patients. *Frontiers in Neurology*. 5.
28. De Las Rivas, J., and C. Fontanillo. 2010. Protein-protein interactions essentials: key concepts to building and analyzing interactome networks. *PLoS Comput Biol*. 6:e1000807.

29. De Masi, R., D. Vergara, S. Pasca, R. Acierno, M. Greco, L. Spagnolo, E. Blasi, F. Sanapo, G. Trianni, and M. Maffia. 2009. PBMCs protein expression profile in relapsing IFN-treated multiple sclerosis: A pilot study on relation to clinical findings and brain atrophy. *J Neuroimmunol.* 210:80-86.
30. Didonna, A., and P. Opal. 2019. The role of neurofilament aggregation in neurodegeneration: lessons from rare inherited neurological disorders. *Molecular neurodegeneration.* 14:19.
31. Dumont, D., J.P. Noben, J. Raus, P. Stinissen, and J. Robben. 2004. Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. *Proteomics.* 4:2117-2124.
32. Dutton, G.N. 2004. Congenital disorders of the optic nerve: excavations and hypoplasia. *Eye (Lond).* 18:1038-1048.
33. Eaton, S.L., S.L. Roche, M. Llaverro Hurtado, K.J. Oldknow, C. Farquharson, T.H. Gillingwater, and T.M. Wishart. 2013. Total protein analysis as a reliable loading control for quantitative fluorescent Western blotting. *PLoS One.* 8:e72457.
34. Farias, A.S., D. Martins-de-Souza, L. Guimaraes, F. Pradella, A.S. Moraes, G. Facchini, J.C. Novello, and L.M. Santos. 2012. Proteome analysis of spinal cord during the clinical course of monophasic experimental autoimmune encephalomyelitis. *Proteomics.* 12:2656-2662.
35. Fazeli, A.S., D. Nasrabadi, A. Pouya, S. Mirshavaladi, M.H. Sanati, H. Baharvand, and G.H. Salekdeh. 2013. Proteome analysis of post-transplantation recovery mechanisms of an EAE model of multiple sclerosis treated with embryonic stem cell-derived neural precursors. *J Proteomics.* 94:437-450.
36. Fazeli, A.S., D. Nasrabadi, M.H. Sanati, A. Pouya, S.M. Ibrahim, H. Baharvand, and G.H. Salekdeh. 2010. Proteome analysis of brain in murine experimental autoimmune encephalomyelitis. *Proteomics.* 10:2822-2832.
37. Gauci, V.J., M.P. Padula, and J.R. Coorsen. 2013. Coomassie blue staining for high sensitivity gel-based proteomics. *J Proteomics.* 90:96-106.
38. Goldberg, J., T. Clarner, C. Beyer, and M. Kipp. 2015. Anatomical Distribution of Cuprizone-Induced Lesions in C57BL/6 Mice. *J Mol Neurosci.* 57:166-175.
39. Gonzalez, C.G., S.K. Tankou, L.M. Cox, E.P. Casavant, H.L. Weiner, and J.E. Elias. 2019. Latent-period stool proteomic assay of multiple sclerosis model indicates protective capacity of host-expressed protease inhibitors. *Sci Rep.* 9:12460.
40. Guido, W. 2018. Development, form, and function of the mouse visual thalamus. *Journal of neurophysiology.* 120:211-225.
41. Hammack, B.N., K.Y. Fung, S.W. Hunsucker, M.W. Duncan, M.P. Burgoon, G.P. Owens, and D.H. Gilden. 2004. Proteomic analysis of multiple sclerosis cerebrospinal fluid. *Mult Scler.* 10:245-260.
42. Hasan, M., H. Min, K.A. Rahaman, A.R. Muresan, H. Kim, D. Han, and O.S. Kwon. 2019. Quantitative Proteome Analysis of Brain Subregions and Spinal Cord from Experimental Autoimmune Encephalomyelitis Mice by TMT-Based Mass Spectrometry. *Proteomics.* 19:e1800355.
43. Hirata, K., J. He, Y. Hirakawa, W. Liu, S. Wang, and M. Kawabuchi. 2003. HSP27 is markedly induced in Schwann cell columns and associated regenerating axons. *Glia.* 42:1-11.
44. Hiremath, M.M., Y. Saito, G.W. Knapp, J.P. Ting, K. Suzuki, and G.K. Matsushima. 1998. Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice. *J Neuroimmunol.* 92:38-49.
45. Hu, X., S. Du, J. Yu, X. Yang, C. Yang, D. Zhou, Q. Wang, S. Qin, X. Yan, L. He, D. Han, and C. Wan. 2016. Common housekeeping proteins are upregulated in colorectal adenocarcinoma and hepatocellular carcinoma, making the total protein a better "housekeeper". *Oncotarget.* 7:66679-66688.
46. Huberman, A.D., and C.M. Niell. 2011. What can mice tell us about how vision works? *Trends in neurosciences.* 34:464-473.
47. Jain, M.R., S. Bian, T. Liu, J. Hu, S. Elkabes, and H. Li. 2009. Altered proteolytic events in experimental autoimmune encephalomyelitis discovered by iTRAQ shotgun proteomics analysis of spinal cord. *Proteome Sci.* 7:25.
48. Jain, M.R., Q. Li, T. Liu, J. Rinaggio, A. Ketkar, V. Tournier, K. Madura, S. Elkabes, and H. Li. 2012. Proteomic Identification of Immunoproteasome Accumulation in Formalin-Fixed Rodent Spinal Cords with Experimental Autoimmune Encephalomyelitis. *Journal of Proteome Research.* 11:1791-1803.
49. Jastorff, A.M., K. Haegler, G. Maccarrone, F. Holsboer, F. Weber, T. Ziemssen, and C.W. Turck. 2009. Regulation of proteins mediating neurodegeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. *Proteomics Clin Appl.* 3:1273-1287.
50. Jia, Y., T. Wu, C.A. Jelinek, B. Bielekova, L. Chang, S. Newsome, S. Gnanapavan, G. Giovannoni, D. Chen, P.A. Calabresi, A. Nath, and R.J. Cotter. 2012. Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS). *Clin Proteomics.* 9:9.
51. Jones-Odeh, E., and C.J. Hammond. 2015. How strong is the relationship between glaucoma, the retinal nerve fibre layer, and neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis? *Eye.* 29:1270-1284.
52. Jung, J.H., Y.W. Ji, H.S. Hwang, J.W. Oh, H.C. Kim, H.K. Lee, and K.P. Kim. 2017. Proteomic analysis of human lacrimal and tear fluid in dry eye disease. *Scientific reports.* 7:13363.
53. Kale, N. 2016. Optic neuritis as an early sign of multiple sclerosis. *Eye Brain.* 8:195-202.
54. Kanamoto, T., T. Tachibana, Y. Kitaoka, T. Hisatomi, Y. Ikeda, Y. Murakami, K. Tobiume, R. Asaoka, and Y. Kiuchi. 2019. Effect of ocular hypertension on D-β-Aspartic acid-containing proteins in the retinas of rats. *Journal of ophthalmology.* 2019.
55. Keskin, O., N. Tuncbag, and A. Gursoy. 2016. Predicting Protein-Protein Interactions from the Molecular to the Proteome Level. *Chem Rev.* 116:4884-4909.
56. Kesler, A., and A.D. Korczyn. 2006. Visual disturbances in Parkinson's disease. *Practical Neurology.* 6:28-33.
57. Kipp, M., T. Clarner, J. Dang, S. Copray, and C. Beyer. 2009. The cuprizone animal model: new insights into an old story. *Acta Neuropathol.* 118:723-736.
58. Kiyota, N., Y. Shiga, S. Suzuki, M. Sato, N. Takada, S. Maekawa, K. Omodaka, K. Maruyama, H. Kunikata, and T. Nakazawa. 2017. The Effect of Systemic Hyperoxia on Optic Nerve Head Blood Flow in Primary Open-Angle Glaucoma Patients. *Invest Ophthalmol Vis Sci.* 58:3181-3188.
59. Krishnamoorthy, G., and H. Wekerle. 2009. EAE: an immunologist's magic eye. *Eur J Immunol.* 39:2031-2035.
60. Kroksveen, A.C., E. Aasebo, H. Vethe, V. Van Pesch, D. Franciotta, C.E. Teunissen, R.J. Ulvik, C. Vedeler, K.M. Myhr, H. Barsnes, and F.S. Berven. 2013. Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM. *J*

61. Kroksveen, A.C., A. Guldbrandsen, C. Vedeler, K.M. Myhr, J.A. Opsahl, and F.S. Berven. 2012. Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls. *Acta Neurol Scand Suppl*:90-96.
62. Langwińska-Wośko, E., K. Szulborski, and K. Broniek-Kowalik. 2012. Visual evoked potentials in early diagnosis of demyelinating diseases—a case report of Devic's disease. *Medical science monitor : international medical journal of experimental and clinical research*. 18:Cs82-84.
63. Lanneau, D., A. de Thonel, S. Maurel, C. Didelot, and C. Garrido. 2007. Apoptosis versus cell differentiation: role of heat shock proteins HSP90, HSP70 and HSP27. *Prion*. 1:53-60.
64. Leocani, L., S. Guerrieri, and G. Comi. 2018. Visual Evoked Potentials as a Biomarker in Multiple Sclerosis and Associated Optic Neuritis. *Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society*. 38:350-357.
65. Liberek, K., A. Lewandowska, and S. Zietkiewicz. 2008. Chaperones in control of protein disaggregation. *The EMBO journal*. 27:328-335.
66. Linker, R.A., P. Brechlin, S. Jesse, P. Steinacker, D.H. Lee, A.R. Asif, O. Jahn, H. Tumani, R. Gold, and M. Otto. 2009. Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage. *PLoS One*. 4:e7624.
67. Liu, S., S. Bai, Z. Qin, Y. Yang, Y. Cui, and Y. Qin. 2009. Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis. *J Cell Mol Med*. 13:1586-1603.
68. Liu, T., K.C. Donahue, J. Hu, M.P. Kurnellas, J.E. Grant, H. Li, and S. Elkabes. 2007. Identification of differentially expressed proteins in experimental autoimmune encephalomyelitis (EAE) by proteomic analysis of the spinal cord. *J Proteome Res*. 6:2565-2575.
69. Ly, L., M.H. Barnett, Y.Z. Zheng, T. Gulati, J.W. Prineas, and B. Crossett. 2011. Comprehensive tissue processing strategy for quantitative proteomics of formalin-fixed multiple sclerosis lesions. *J Proteome Res*. 10:4855-4868.
70. Manogaran, P., M. Samardzija, A.N. Schad, C.A. Wicki, C. Walker-Egger, M. Rudin, C. Grimm, and S. Schippling. 2019. Retinal pathology in experimental optic neuritis is characterized by retrograde degeneration and gliosis. *Acta Neuropathologica Communications*. 7:116.
71. Martin, N.A., V. Molnar, G.T. Szilagy, M.L. Elkjaer, A. Nawrocki, J. Okarmus, A. Wlodarczyk, E.K. Thygesen, M. Palkovits, F. Gallyas, M.R. Larsen, H. Lassmann, E. Benedikz, T. Owens, A.F. Svenningsen, and Z. Illes. 2018. Experimental Demyelination and Axonal Loss Are Reduced in MicroRNA-146a Deficient Mice. *Frontiers in Immunology*. 9.
72. Martínez-Lapiscina, E.H., B. Sanchez-Dalmau, E. Fraga-Pumar, S. Ortiz-Perez, A.I. Tercero-Urbe, R. Torres-Torres, and P. Villoslada. 2014. The visual pathway as a model to understand brain damage in multiple sclerosis. *Multiple sclerosis (Houndmills, Basingstoke, England)*. 20:1678-1685.
73. Matsushima, G.K., and P. Morell. 2001. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. *Brain Pathol*. 11:107-116.
74. Mesulam, M., and C. Geula. 1991. Differential distribution of a neurofilament protein epitope in acetylcholinesterase-rich neurons of human cerebral neocortex. *Brain Res*. 544:169-173.
75. Mi, H., A. Muruganujan, D. Ebert, X. Huang, and P.D. Thomas. 2018. PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. *Nucleic acids research*. 47:D419-D426.
76. Michaels, T.C., H.W. Lazell, P. Arosio, and T.P. Knowles. 2015. Dynamics of protein aggregation and oligomer formation governed by secondary nucleation. *J Chem Phys*. 143:054901.
77. Mosser, D.D., and R.I. Morimoto. 2004. Molecular chaperones and the stress of oncogenesis. *Oncogene*. 23:2907-2918.
78. Mozziconacci, J., L. Sandblad, M. Wachsmuth, D. Brunner, and E. Karsenti. 2008. Tubulin dimers oligomerize before their incorporation into microtubules. *PLoS One*. 3:e3821.
79. Nagashima, M., C. Fujikawa, K. Mawatari, Y. Mori, and S. Kato. 2011. HSP70, the earliest-induced gene in the zebrafish retina during optic nerve regeneration: its role in cell survival. *Neurochemistry international*. 58:888-895.
80. Nakamura, M., M. Araki, K. Oguro, and T. Masuzawa. 1992. Differential distribution of 68 Kd and 200 Kd neurofilament proteins in the gerbil hippocampus and their early distributional changes following transient forebrain ischemia. *Exp Brain Res*. 89:31-39.
81. Namekata, K., A. Kimura, C. Harada, H. Yoshida, Y. Matsumoto, and T. Harada. 2014. Dock3 protects myelin in the cuprizone model for demyelination. *Cell Death Dis*. 5:e1395.
82. Nguyen, T., N.R. Mehta, K. Conant, K.-J. Kim, M. Jones, P.A. Calabresi, G. Melli, A. Hoke, R.L. Schnaar, and G.-L. Ming. 2009. Axonal protective effects of the myelin-associated glycoprotein. *Journal of Neuroscience*. 29:630-637.
83. Nie, X., C. Li, S. Hu, F. Xue, Y.J. Kang, and W. Zhang. 2017. An appropriate loading control for western blot analysis in animal models of myocardial ischemic infarction. *Biochemistry and biophysics reports*. 12:108-113.
84. Noaman, N., P.S. Abbineni, M. Withers, and J.R. Coorssen. 2017. Coomassie staining provides routine (sub) femtomole in-gel detection of intact proteoforms: Expanding opportunities for genuine Top-down Proteomics. *Electrophoresis*. 38:3086-3099.
85. Noaman, N., and J.R. Coorssen. 2018. Coomassie does it (better): A Robin Hood approach to total protein quantification. *Anal Biochem*. 556:53-56.
86. Noben, J.P., D. Dumont, N. Kwasnikowska, P. Verhaert, V. Somers, R. Hupperts, P. Stinissen, and J. Robben. 2006. Lumbar cerebrospinal fluid proteome in multiple sclerosis: characterization by ultrafiltration, liquid chromatography, and mass spectrometry. *J Proteome Res*. 5:1647-1657.
87. Olesen, M.N., K. Soelberg, B. Debrabant, A.C. Nilsson, S.T. Lillevang, J. Grauslund, I. Brandslund, J.S. Madsen, F. Paul, T.J. Smith, S. Jarius, and N. Asgari. 2019. Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort study. *Journal of neuroinflammation*. 16:59.
88. Oliveira, B.M., J.R. Coorssen, and D. Martins-de-Souza. 2014. 2DE: the phoenix of proteomics. *J Proteomics*. 104:140-150.

89. Ornelas, I.M., L.E. McLane, A. Saliu, A.V. Evangelou, L. Khandker, and T.L. Wood. 2016. Heterogeneity in oligodendroglia: Is it relevant to mouse models and human disease? *Journal of Neuroscience Research*. 94:1421-1433.
90. Oveland, E., A. Nystad, F. Berven, K.M. Myhr, O. Torkildsen, and S. Wergeland. 2018. 1,25-Dihydroxyvitamin-D3 induces brain proteomic changes in cuprizone mice during remyelination involving calcium proteins. *Neurochem Int*. 112:267-277.
91. Partridge, M.A., S. Gopinath, S.J. Myers, and J.R. Coorsen. 2016. An initial top-down proteomic analysis of the standard cuprizone mouse model of multiple sclerosis. *J Chem Biol*. 9:9-18.
92. Paxinos, G., and K. Franklin. 2012. Paxinos and Franklin's the Mouse Brain in Stereotaxic Coordinates, Fourth Edition. Academic Press.
93. Pistorio, A.L., S.H. Hendry, and X. Wang. 2006. A modified technique for high-resolution staining of myelin. *J Neurosci Methods*. 153:135-146.
94. Pohl, H.B.F., C. Porcheri, T. Mueggler, L.C. Bachmann, G. Martino, D. Riethmacher, R.J.M. Franklin, M. Rudin, and U. Suter. 2011. Genetically induced adult oligodendrocyte cell death is associated with poor myelin clearance, reduced remyelination, and axonal damage. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 31:1069-1080.
95. Praet, J., C. Guglielmetti, Z. Berneman, A. Van der Linden, and P. Ponsaerts. 2014. Cellular and molecular neuropathology of the cuprizone mouse model: clinical relevance for multiple sclerosis. *Neurosci Biobehav Rev*. 47:485-505.
96. Procaccini, C., V. De Rosa, V. Pucino, L. Formisano, and G. Matarese. 2015. Animal models of Multiple Sclerosis. *Eur J Pharmacol*. 759:182-191.
97. Rabilloud, T., and C. Lelong. 2011. Two-dimensional gel electrophoresis in proteomics: a tutorial. *J Proteomics*. 74:1829-1841.
98. Ransohoff, R.M. 2012. Animal models of multiple sclerosis: the good, the bad and the bottom line. *Nat Neurosci*. 15:1074-1077.
99. Raphael, I., J. Webb, F. Gomez-Rivera, C.A. Chase Huizar, R. Gupta, B.P. Arulanandam, Y. Wang, W.E. Haskins, and T.G. Forsthuber. 2017. Serum Neuroinflammatory Disease-Induced Central Nervous System Proteins Predict Clinical Onset of Experimental Autoimmune Encephalomyelitis. *Frontiers in Immunology*. 8.
100. Rizzo, J. 2005. Embryology, anatomy, and physiology of the afferent visual pathway. *Clinical Neuro-Ophthalmology*:3-82.
101. Salvisberg, C., N. Tajouri, A. Hainard, P.R. Burkhard, P.H. Lalive, and N. Turck. 2014. Exploring the human tear fluid: discovery of new biomarkers in multiple sclerosis. *Proteomics Clin Appl*. 8:185-194.
102. Sapienza, A., A.-L. Raveu, E. Reboussin, C. Roubeix, C. Boucher, J. Dégardin, D. Godefroy, W. Rostène, A. Reaux-Le Goazigo, C. Baudouin, and S. Melik Parsadaniantz. 2016. Bilateral neuroinflammatory processes in visual pathways induced by unilateral ocular hypertension in the rat. *Journal of neuroinflammation*. 13:44.
103. Seabrook, T.A., T.J. Burbridge, M.C. Crair, and A.D. Huberman. 2017. Architecture, Function, and Assembly of the Mouse Visual System. *Annual review of neuroscience*. 40:499-538.
104. Selhorst, J.B., and Y. Chen. 2009. The optic nerve. *Semin Neurol*. 29:29-35.
105. Semba, R.D., J.J. Enghild, V. Venkatraman, T.F. Dyrland, and J.E. Van Eyk. 2013. The Human Eye Proteome Project: perspectives on an emerging proteome. *Proteomics*. 13:2500-2511.
106. Sen, M.K., M.S. Almuslehi, P.J. Shortland, J.R. Coorsen, and D.A. Mahns. 2020a. Revisiting the Pathoetiology of Multiple Sclerosis: Has the Tail Been Wagging the Mouse? *Frontiers in immunology*. 11.
107. Sen, M.K., M.S. Almuslehi, P.J. Shortland, D.A. Mahns, and J.R. Coorsen. 2021. Proteomics of Multiple Sclerosis: Inherent Issues in Defining the Pathoetiology and Identifying (Early) Biomarkers. *International Journal of Molecular Sciences*. 22:7377.
108. Sen, M.K., M.S.M. Almuslehi, J.R. Coorsen, D.A. Mahns, and P.J. Shortland. 2020b. Behavioural and histological changes in cuprizone-fed mice. *Brain Behav Immun*. 87:508-523.
109. Sen, M.K., M.S.M. Almuslehi, E. Gyengesi, S.J. Myers, P.J. Shortland, D.A. Mahns, and J.R. Coorsen. 2019a. Suppression of the Peripheral Immune System Limits the Central Immune Response Following Cuprizone-Feeding: Relevance to Modelling Multiple Sclerosis. *Cells*. 8.
110. Sen, M.K., D.A. Mahns, J.R. Coorsen, and P.J. Shortland. 2019b. Behavioural phenotypes in the cuprizone model of central nervous system demyelination. *Neurosci Biobehav Rev*. 107:23-46.
111. Sia, P.I., J.P. Wood, G. Chidlow, and R. Casson. 2019. Creatine is Neuroprotective to Retinal Neurons In Vitro But Not In Vivo. *Investigative ophthalmology & visual science*. 60:4360-4377.
112. Singh, V., C. Stingl, M.P. Stoop, L. Zeneyedpour, R.F. Neuteboom, P.S. Smitt, R.Q. Hintzen, and T.M. Luider. 2015. Proteomics urine analysis of pregnant women suffering from multiple sclerosis. *J Proteome Res*. 14:2065-2073.
113. Sofroniew, M.V., and H.V. Vinters. 2010. Astrocytes: biology and pathology. *Acta Neuropathol*. 119:7-35.
114. Soto, C., and S. Pritzkow. 2018. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. *Nature neuroscience*. 21:1332-1340.
115. Stoop, M.P., T. Rosenling, A. Attali, R.J. Meesters, C. Stingl, L.J. Dekker, H. van Aken, E. Suidgeest, R.Q. Hintzen, T. Tuinstra, A. van Gool, T.M. Luider, and R. Bischoff. 2012. Minocycline effects on the cerebrospinal fluid proteome of experimental autoimmune encephalomyelitis rats. *J Proteome Res*. 11:4315-4325.
116. Stys, P.K., G.W. Zamponi, J. Van Minnen, and J.J. Geurts. 2012. Will the real multiple sclerosis please stand up? *Nature Reviews Neuroscience*. 13:507-514.
117. Szilagyi, G.T., A.M. Nawrocki, K. Eros, J. Schmidt, K. Fekete, M.L. Elkjaer, K.H. Hyrlov, M.R. Larsen, Z. Illes, and F. Gallyas, Jr. 2020. Proteomic changes during experimental de- and remyelination in the corpus callosum. *PLoS One*. 15:e0230249.

118. Szklarczyk, D., A.L. Gable, D. Lyon, A. Junge, S. Wyder, J. Huerta-Cepas, M. Simonovic, N.T. Doncheva, J.H. Morris, P. Bork, L.J. Jensen, and Christian v. Mering. 2018. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Research*. 47:D607-D613.
119. Taveggia, C., P. Thaker, A. Petrylak, G.L. Caporaso, A. Toews, D.L. Falls, S. Einheber, and J.L. Salzer. 2008. Type III neuregulin-1 promotes oligodendrocyte myelination. *Glia*. 56:284-293.
120. Teo, W., A.V. Capriarello, M.L. Morgan, A. Luchicchi, G.J. Schenk, J.T. Joseph, J.J.G. Geurts, and P.K. Stys. 2021. Nile Red fluorescence spectroscopy reports early physicochemical changes in myelin with high sensitivity. *Proc Natl Acad Sci U S A*. 118.
121. Traka, M., K. Arasi, R.L. Avila, J.R. Podojil, A. Christakos, S.D. Miller, B. Soliven, and B. Popko. 2010. A genetic mouse model of adult-onset, pervasive central nervous system demyelination with robust remyelination. *Brain*. 133:3017-3029.
122. Turturici, G., R. Tinnirello, G. Sconzo, A. Asea, G. Savettieri, P. Ragonese, and F. Geraci. 2014. Positive or negative involvement of heat shock proteins in multiple sclerosis pathogenesis: An overview. *Journal of Neuropathology & Experimental Neurology*. 73:1092-1106.
123. Vanheel, A., R. Daniels, S. Plaisance, K. Baeten, J.J. Hendriks, P. Leprince, D. Dumont, J. Robben, B. Brone, P. Stinissen, J.P. Noben, and N. Hellings. 2012. Identification of protein networks involved in the disease course of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. *PLoS One*. 7:e35544.
124. Varhaug, K.N., Ø. Torkildsen, K.-M. Myhr, and C.A. Vedeler. 2019. Neurofilament Light Chain as a Biomarker in Multiple Sclerosis. *Frontiers in Neurology*. 10.
125. Wang, Y.H., D.W. Wang, N. Wu, Y. Wang, and Z.Q. Yin. 2012. alpha-Crystallin promotes rat axonal regeneration through regulation of RhoA/rock/cofilin/MLC signaling pathways. *Journal of Molecular Neuroscience*. 46:138-144.
126. Werner, S.R., J.K. Saha, C.L. Broderick, E.Y. Zhen, R.E. Higgs, K.L. Duffin, and R.C. Smith. 2010. Proteomic analysis of demyelinated and remyelinating brain tissue following dietary cuprizone administration. *J Mol Neurosci*. 42:210-225.
127. Wright, E.P., M.A. Partridge, M.P. Padula, V.J. Gauci, C.S. Malladi, and J.R. Coorsen. 2014. Top-down proteomics: enhancing 2D gel electrophoresis from tissue processing to high-sensitivity protein detection. *Proteomics*. 14:872-889.
128. Yang, H.J., H. Wang, Y. Zhang, L. Xiao, R.W. Clough, R. Browning, X.M. Li, and H. Xu. 2009. Region-specific susceptibilities to cuprizone-induced lesions in the mouse forebrain: Implications for the pathophysiology of schizophrenia. *Brain Res*. 1270:121-130.
129. Yuan, A., M.V. Rao, T. Sasaki, Y. Chen, A. Kumar, R.K. Liem, J. Eyer, A.C. Peterson, J.-P. Julien, and R.A. Nixon. 2006. α -Internexin is structurally and functionally associated with the neurofilament triplet proteins in the mature CNS. *Journal of Neuroscience*. 26:10006-10019.
130. Zhan, X., B. Li, X. Zhan, H. Schlüter, P.R. Jungblut, and J.R. Coorsen. 2019. Innovating the Concept and Practice of Two-Dimensional Gel Electrophoresis in the Analysis of Proteomes at the Proteoform Level. *Proteomes*. 7.
131. Zhang, R., D. Yang, C. Zhou, K. Cheng, Z. Liu, L. Chen, L. Fang, and P. Xie. 2012. β -actin as a loading control for plasma-based Western blot analysis of major depressive disorder patients. *Analytical biochemistry*. 427:116-120.

Figures

Figure 1

Overview of top-down proteomic analysis of optic nerve/tract The top-down proteomic analysis consisted of 6 general steps. 1) Optic nerve/tract samples were collected after dissection (pooled from 5 animals/treatment group) and snap frozen with liquid nitrogen. 2) Samples were homogenized in a deep-frozen state (i.e. automated frozen disruption), solubilized, and fractionated into total soluble and membrane proteomes. 3) Proteoforms were resolved based on charge (pI) using immobilized pH gradient strips and then by size (~MW) using SDS-PAGE, and detected using cCBB. 4) Spots were analysed using Delta 2D software to identify quantitative differences between the Ctrl and CPZ groups; these spots were excised from the gel and digested using trypsin. 5) Peptides were analysed by LC-TMS and the corresponding canonical amino acid sequences of the resolved proteoforms were identified using ProteinLynx Global Server (PLGs) and Swiss-Prot databases. 6) Literature mining and bioinformatic analyses were used to assess potential functions and interactions (Sen et al., 2019a).

Figure 2

Quantification of demyelination and gliosis. A) Representative images of silver-stained whole brain coronal sections and the regions of interest from Ctrl and CPZ-fed mice. B) Quantification of staining (a - c); CPZ-feeding produced significant changes in silver staining (a, n=5 sections/animal, 5 animals/group) in the corpus callosum (CC). GFAP (b, 3-5 sections/animal, 3-5 animals/group) and IBA 1-stained glia (c, 3-5 sections/animal, 3-5 animals/group) were significantly increased only in the corpus callosum (CC). Data are presented as mean $\pm$ SEM. A two-tailed t-test was used to determine differences between groups (*p<0.05). Abbreviations: AU, arbitrary unit; CC, corpus callosum; OT, optic tract; PN, pretectal nucleus; VC, visual cortex; LGN, lateral geniculate nucleus and SC, superior colliculus. Images of silver stained pretectal and lateral geniculate nuclei are shown in Supplementary Figure 1 and representative images of GFAP and IBA 1 are shown in Supplementary Figure 2.

Figure 3

Top-down proteomic analysis. A) Representative examples of two-dimensional gel images of the soluble and membrane sub-proteomes from the optic nerves/tracts of naïve Ctrl and 0.1% CPZ-fed mice. Proteoforms were resolved based on their isoelectric point (pI) and molecular weight (MW). Image analysis revealed a total of 34 spots that increased (green circles) or decreased (red circles) in abundance in the CPZ samples relative to the controls. The identities of the protein species for the circled spots are shown in Table 1 and Supplementary Table 1. B) There was no significant difference in the total number of spots between Ctrl and CPZ for both the resolved soluble and membrane sub-proteomes. Data are presented as mean $\pm$ SEM (n=3 gels/fraction, n=5 animals/group). C) Comparison between experimental and theoretical MW (upper-right graph) and pI (lower-right graph) of the identified proteoforms. Purple dashed line indicates 95% confidence intervals.

Figure 4

Functional clustering and protein–protein interactions. Pie charts show the distribution of identified proteoforms according to (A) Subcellular localizations (characterized using UniProt), (B) Protein classes (categorized using PANTHER), (C) Biological processes (categorized using PANTHER), and (D) Molecular functions (via literature search). (E) Protein–protein interactions association network maps. The strength of interactions is indicated by the thickness of the lines. The colour coding of proteins in the STRING is based on the molecular functions (D).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplemenatryTable1.docx](#)
- [Supplementaryfigure1.tif](#)
- [Supplementaryfigure2.tif](#)
- [Supplementaryfigure3.tif](#)